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Organophosphate (OP)-containing pesticides are extensively used worldwide for 
domestic and industrial purposes.  Studies on acute and chronic exposure to OPs have 
revealed numerous health effects attributed mainly to acetylcholinesterase inhibition.  
The enzyme human serum paraoxonase (PON1) is involved in the detoxification of 
OP compounds.  PON1 polymorphisms have been shown to affect susceptibility to 
OP exposure.  In this study, we investigated the effect of OP exposure on pest control 
workers using cholinesterase levels as biomarkers of toxicity.  Next we determined 
PON1 activity towards two OP substrates (paraoxon and diazoxon) of our sample as 
well as the distribution of two common PON1 polymorphisms in our local population 
(PON1Q192R and PON1L55M) and assessed whether these factors were involved in 
OP toxicity. 
 
The exposed group consisted of 103 workers from various pest control companies 
under the Singapore Pest Management Association while the 91 unexposed workers 
were from a lead stabiliser factory.  For all workers, the mean age was 36.9 (20–70) 
years and the ethnic distribution was 38.1% Chinese, 44.3% Malay and 17.5% Indian.  
The mean ± SD exposure duration among the pesticide workers was 10.4 ± 8.4 years. 
The mean ± SD erythrocyte cholinesterase level was 18436.2 ± 2078 U/L and 18079.6 
± 1576 U/L for the exposed and unexposed groups respectively (p=0.216).  The mean 
± SD serum pseudocholinesterase level was 11028.4 ± 2867.4 U/L and 9433.6 ± 
2022.6 U/L in the exposed and unexposed groups respectively (p<0.0001).  The mean 
± SD paraoxonase levels in the exposed and unexposed groups were 299.4 ± 135.0 
U/L and 178.2 ± 58.1 U/L respectively (p<0.0001).  The mean ± SD diazoxonase 
levels in the exposed and unexposed groups were 1525.6 ± 635.0 U/L and 1929.3 ± 
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905.7 U/L respectively (p=0.0007).  Mean paraoxonase activity was similar among 
Chinese and Malays (266.5 U/L and 266.3 U/L respectively) whereas that of the 
Indians was significantly lower (165.6 U/L).  The R and L allele, which confer higher 
PON1 activity and higher PON1 levels respectively, were found in higher frequencies 
in Malays and Chinese compared to Indians. 
 
Our study showed that cholinesterase levels among the exposed were not lower than 
those in the unexposed group.  PON1 activity and consequently PON1 
polymorphisms differed among ethnic groups, implying that ethnicity could be an 
important surrogate for identifying susceptible groups in case of OP exposure.  
Although OP poisoning is rare among occupationally exposed workers in Singapore, 
this information would be useful for other developing countries that have large 
populations of Chinese, Malays and Indians where OP exposure could be very high 
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INTRODUCTION 
Organophosphates (OPs) are esters of phosphoric acid produced by the reaction of 
alcohols and phosphoric acid.  OPs are widely used as insecticides worldwide and 
they are readily available commercially for domestic and industrial purposes. In 
addition, OPs are also utilised as therapeutic agents in the treatment of ophthalmic 
conditions (e.g. echothiophate, isoflurophate) (Lloyd 1963) and as antihelmintics 
(trichlorfon) (Harder 2002), as well as nerve agents in chemical warfare (e.g. sarin, 
soman) (Holstege et al. 1997).  Bioactivation of OP compounds converts them from 
their relatively non-toxic form into very highly toxic oxon forms.  In this form, they 
are very strong cholinesterase inhibitors and cause toxicity through cholinesterase 
inhibition. 
 
OPs are widely used in agriculture as insecticides and herbicides as they are readily 
available commercially for domestic and industrial purposes.  This is especially true 
in developing countries where they are more affordable than newer options.  Even in a 
developed country like Singapore where different kinds of pesticides are highly 
accessible, OPs are still being used in the pest management industry.  Therein exists 
the problem of pesticide poisoning because of its wide usage. The World Health 
Organisation (WHO) estimated that acute pesticide poisoning affects as many as 39 
million people around the world (WHO/United Nations Environment Programme 
1990).  Despite this shocking figure, there is presently no global system to track 
poisonings or diseases closely related to pesticide use.  WHO also estimated that two 
million cases and 220000 deaths occur due to acute pesticide poisonings worldwide.  
These account for only a tiny fraction of the actual number of cases because these 
estimates are based on government records of pesticide-related hospitalisations while 
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the vast majority of acute pesticide-related illnesses do not result in hospitalisation or 
may not have been reported.  Although research documenting detrimental health 
effects of OP exposure has prompted many western countries to ban OP usage, OP 
pesticides are still being widely used in Asia (Pesticide Action Network UK 1993).  A 
survey conducted in Asian countries estimated that on average, 3% of agricultural 
workers in developing countries suffer an episode of pesticide poisoning a year 
(WHO/United Nations Environment Programme 1990). 
 
In addition to OPs being a health hazard in agriculture, there is increasing worry about 
the adoption of such chemicals in terrorism and chemical warfare.  In 1994, civilians 
in Matsumoto, Japan were attacked with sarin gas, resulting in the deaths of seven 
people and almost 200 persons needing medical attention (Morita et al. 1995).  This 
preceded another unfortunate incident in Tokyo in 1995 whereby sarin was released in 
subways, killing 10 people while injuring over 5000 (Suzuki et al. 1995).  These 
chemical warfare agents have also been exploited as weapons of mass destruction and 
have caused, for instance, suspected accidental exposure to military personnel during 
the Gulf War resulting in many Gulf War veterans still suffering from OP poisoning 
effects today (McCauley et al. 2001). 
 
What is the situation like in Singapore?  Here, pesticide usage is tightly regulated.  
Under the Control of Vectors and Pesticides Act 1998, all public health pesticide 
products and repellents intended for use against the five vectors (i.e. mosquitoes, flies, 
cockroaches, rodents and rat fleas) in Singapore are required to be registered by the 
National Environment Agency (NEA) of Singapore prior to local sale (National 
Environmental Agency 2004).  OP pesticides (i.e. pesticides containing an 
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organophosphorous group, an organochlorine group or a carbamate group) are 
controlled under the Environmental Pollution Control Act 1999 and require the 
Poisons Licence and Permit. They are also required to be registered as long as they 
are used against the five vectors stated above.  Apart from the tight regulations above, 
workers handling pesticides are also required to undergo health surveillance every six 
months to monitor their cholinesterase levels. 
 
While these measures are in place, to date, there have been no known reported studies 
on pesticide exposure in Singapore.   An investigation into the exposure levels, using 
cholinesterase levels as biomarkers of OP toxicity, among our pesticide workers 
would give an important insight onto whether these regulatory measures are effective.  
As an extension to this, it would be interesting to find out the different factors that 
might affect susceptibility to OP toxicity namely paraoxonase-1 (PON1) levels, which 
is the main enzyme involved in detoxification of OP compounds.  As paraoxonase 
levels are governed by genetic polymorphisms in the PON1 gene, we also sought to 
study the effect of this on PON1 and cholinesterase levels.  These in turn are affected 
by ethnicity, hence, our population being multi-ethnic, enabled us to look into these 
differences.  With these pointers in mind, we carried out the following study with the 
hope of studying the exposure status of pesticide workers in Singapore while at the 
same time establishing the phenotypic and genotypic characteristics of PON1 in the 
Indians, Malays and Chinese here. 
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LITERATURE REVIEW  
Organophosphates 
Structure and properties of organophosphates 
OPs are produced by the reaction of alcohols and phosphoric acid to make esters of 
phosphoric acid.  They are made up of a structure consisting of a phosphorous atom 
linked to a sulphur or oxygen atom via a double bond (Figure 1).  The phosphorus 
atom is esterified by two alkyl chains and the remaining bond contains a chemical 
moiety that differs widely among different types of OPs. This leaving group could be 
an alkyl, alkoxy, alkylthio, aryl or heterocyclic, aryloxy or a heterocyclic analog. 
 




Three commonly used organophosphorous insecticides – parathion, diazinon and 
chlorpyrifos, contain a sulphur atom attached to the phosphorus atom.  In their 
original form, these molecules are relatively non-toxic.  However, bioactivation by 
cytochrome P450 enzymes (including CYP 3A4) (Sams et al. 2000) convert them to 
very highly toxic oxon forms (i.e. paraoxon, diazoxon and chlorpyrifos-oxon 
respectively). This bioactivation involves the removal of the sulphur atom and 
replacement with an oxygen atom.  The oxon forms are strong cholinesterase 
inhibitors and cause death through cholinesterase inhibition.  Detoxification of these 
toxic oxon forms occur through the same cytochrome P450 enzymes involved in their 
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bioactivation, and also through conjugation with glutathione and hydrolysis by 
esterases found in many mammalian species e.g. carboxylesterase and PON1.  The 
nerve agents sarin and soman do not require bioactivation and can be hydrolysed 
directly by PON1.  Figure 2 shows the chemical pathways of activation and 












Figure 2.  Biodegradation of OP compounds – parathion, chlorpyrifos, diazinon, 
sarin and soman by PON1. (Adapted from Davies et al. 1996) 
 
 
Applications of organophosphates 
OPs are largely used in agriculture as insecticides and herbicides.  They are readily 
available commercially for domestic and industrial purposes. OPs are the most 
commonly used group of insecticides worth nearly 40% of the global market 
(Pesticide Action Network UK 1996).  OPs are widely used in developing countries as 



















































































































there is high accessibility to different kinds of pesticides, OPs are still being used in 
the pest management industry. 
 
OPs are used widely as solvents, plasticisers and extreme pressure (EP) additives 
(Thomas and Macaskie 1996; Carlsson et al. 1997).  In addition, OPs are also utilised 
as therapeutic agents in the treatment of ophthalmic conditions (e.g. echothiophate, 
isoflurophate) (Lloyd 1963), as antihelmintics (trichlorfon) (Harder 2002), and even 
in the treatment of Alzheimer’s disease (Imbimbo 2001).  OPs have also been used as 
nerve agents in chemical warfare (e.g. sarin, soman) (Holstege et al. 1997). 
 
Organophosphate toxicity 
OPs exert their toxicity by inhibiting the enzyme acetylcholinesterase (AChE) in the 
nervous system. This enzyme catalyses the hydrolysis of acetylcholine, a major 
neurotransmitter in the central and peripheral nervous system, into choline and acetic 
acid.  When AChE is inactivated by phosphorylation of the serine hydroxyl group at 
the active site of AChE, acetylcholine released from nerve terminals accumulates and 
over-stimulation of muscarinic and nicotinic receptors occurs (Ecobichon 2001).  OPs 
can be ingested, inhaled, absorbed through the skin or injected. The schematic in 
Figure 3 depicts what happens during AChE inactivation at nerve terminals (Adapted 
from Pope et al. 2005).  
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Figure 3.  The cholinergic mechanism at synapses. Usually, acetylcholine (ACh) released 
by the presynaptic terminal is hydrolysed by AChE.  Choline is released and transported back into the 
presynaptic terminal by the high affinity choline uptake (HACU) process.  Choline acetyltransferase 
(ChAT) forms acetylcholine using choline and acetyl coenzyme A.  Synaptic vesicles fuse with the 
plasma membrane and release acetylcholine into the cleft upon terminal depolarisation.  When enough 
cholinesterase inhibitors bind to AChE to (1) block transmitter degradation, acetylcholine accumulates 
in the synaptic cleft (2).  This results in constant stimulation of cholinergic receptors on the 
postsynaptic cell (3).  Excessive activation of these postsynaptic receptors results in prolonged receptor 
signalling (4) and related changes in postsynaptic cell function. 
 
 
The clinical features of OP poisoning manifest in the form of a cholinergic crisis.  The 
onset of symptoms occurs within hours of exposure and this may include collapse, 
sweating, breathing problems, excessive salivation, diarrhoea, vomiting, heart 
dysrrthymias and extreme anxiety.  Cardiac or respiratory failure may lead to death.  
The onset and severity of symptoms is dependent on the type of OP, amount, route of 
exposure and rate of metabolic degradation.  In mild cases, symptoms are usually 
treated with oximes (e.g. pralidoxime chloride) which reactivate phosphorylated 
AChE.  Treatment may be augmented with atropine which is an acetylcholine 
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antagonist that prevents the action of acetylcholine on muscarinic receptors (Namba et 
al. 1971).  Supplementary pharmacological treatment with diazepam and supportive 
treatment through artificial ventilation may be employed in cases of severe poisoning 
(Lotti 2001). 
 
Several OPs are capable of causing organophosphate-induced delayed polyneuropathy 
(OPIDP). This happens when neurons are killed due to acute or chronic OP poisoning 
and its onset is usually a few days up to two-three weeks after poisoning.  Signs and 
symptoms include sharp, cramp-like pains in the calves, tingling of the hands and feet, 
followed by distal numbness and parathesia. The molecular target for OPIDP is 
neuropathy target esterase (NTE), which has esteratic activity towards phenyl 
phenylacetate, phenylvalerate or closely related esters. Although there may be some 
functional recovery, motor neurons may permanently lose function (Jokanovic et al. 
2002). 
 
In addition to the neurotoxic effects stated above, OPs have also been implicated in 
developmental (neuro)toxicity.  Experimental data has shown that young animals are 
more sensitive to the effects of exposure owing to their lower metabolic capabilities 
(Pope and Liu 1997; Vidair 2004).  The mechanisms suggested for these effects 
include inhibition of brain AChE, downregulation of muscarinic receptors, decreased 
brain DNA synthesis and reduced brain weight in offspring. Young children are also 
expected to be more sensitive to acute toxicity than adults through extrapolation of 
animal data.  Indeed it has been shown that levels of chlorpyrifos in umbilical cord 
plasma of mothers exposed to pesticides were inversely associated with birth weight 
and length (Whyatt et al. 2004).  The routes of exposure in children are similar to 
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adults but due to children’s hand-to-mouth behaviour, breastfeeding from exposed 
mothers and increased time spent outdoors, their likelihood of exposure is greater than 
adults.  Parental exposure to pesticides or application of pesticides in the home has 
been linked to respiratory health effects, childhood brain tumours, leukemias and 
lymphomas, testicular and other cancers, and neural tube and other birth defects 
(Buckley et al. 1989; Blair et al. 1992; Kristensen et al. 1996; Blatter et al. 1997). 
 
Toxicity to OPs may be significantly affected by genetic differences in the enzymes 
involved in the bioactivation and detoxification of OPs, as well as the enzymes 
targeted by these compounds (Costa 2001).  The focus of this project is on PON1 but 
polymorphisms in cytochromes P450 (CYP), glutathione-S-transferases (GST) as well 
as of erythrocyte acetylcholinesterase (RBC AChE) and serum pseudocholinesterase 
(serum PChE) [the latter two discussed below] may also be players in OP toxicity, 
although there is little convincing evidence that proves so to date. 
 
Cholinesterase and organophosphate toxicity 
As mentioned above, the primary target for OP toxicity is AChE.  The discovery that 
OPs inhibited AChE was the basis of development of OPs as pesticides, since the 
insect and mammalian cholinergic nervous systems are highly similar.  OP toxicity is 
clinically diagnosed through measurement of cholinesterase activity.  RBC AChE and 
serum PChE may both be used.  However, RBC AChE is a better indicator of CNS 
cholinesterase because RBC AChE concentrations are presumed to closely reflect the 
effects of OP agents in target organs, if the OP has equal access to the synapses and 
blood.  Hence it is a more useful marker of OP poisoning than serum PChE.  Because 
of this, the measurement of both enzymes has been recommended in clinical 
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toxicology and monitoring of high-risk occupational activities (HSE 2000).  Pesticide 
over-exposure is indicated by a depression of at least 15% from an individual’s 
normal level of serum or erythrocyte enzyme activity.  There is large inter-individual 
variability in cholinesterase levels hence it has been suggested that measuring an 
individual’s cholinesterase level with reference to his baseline values (when not 
exposed) would be more sensitive than comparing it to a ‘population normal average’.  
However, in cases of severe OP exposure, the depression of both serum PChE and 
RBC AChE would be certainly obvious and such measurements would generally not 
be necessary.   
 
RBC AChE is considered a marker of chronic exposure whereas serum PChE is more 
suited for measuring acute toxicity.  This is because while serum PChE recovers 
quickly, within four weeks of OP exposure, RBC AChE takes a longer time 
(recovering at a rate of ~1% per day) and may take as long as several months to be 
restored to normal function.  RBC AChE activity restoration takes place by some 
spontaneous dephosphorylation of the inhibited enzyme and mainly by slow de novo 
synthesis of fresh enzyme.  Inactivation (phosphorylation) and reactivation 
(dephosphorylation) rates differ widely for various OP compounds, accounting for the 
differing toxicity of the various OP agents.  Since one radical is lost (ageing) during 
enzyme inactivation thus making it more stable, spontaneous dephosphorylation does 
not occur.  In this way, there is a relationship between ageing and toxicity, with 





Paraoxonase-1 (PON1) Protein 
Introduction to the PON1 protein 
Human serum paraoxonase (PON1) is a member of the A-esterase family (EC 3.1.8.1) 
that includes PON2 and PON3.  Human PON2 and PON3 are similar to PON1 in that 
they are able to hydrolyse aromatic and long-chain aliphatic lactones (Draganov et al. 
2005). However, they are both distinct from PON1 due to their very limited ability to 
hydrolyse paraoxon. As such, our discussion will focus on the 
paraoxonase/diazoxonase capabilities of PON1 alone.  PON1 derived its name 
originally from its ability to hydrolyse paraoxon.  It is a highly glycosylated protein 
weighing about 44 kDa and consisting of 355 amino acids (Hassett et al. 1991).  
Serum concentration of PON1 is about 50 mg/L (Haagen and Brock 1992).  Early 
studies measuring PON1 paraoxonase activity, using paraoxon as a single substrate, in 
Caucasian subjects revealed a bimodal or trimodal distribution (Eckerson et al. 1983).    
These enzymatic tests were able to divide serum PON1 activity into three phenotypes: 
low, intermediate and high PON1 activity without a clear distinction between 
intermediate and high metabolisers.   
 
Although the physiological role of PON1 has not been established, serum PON1 has 
been recognised to be involved in the detoxification of OP insecticides (reviewed in 
Costa et al. 1999) and nerve agents (Smolen et al. 1991).  It is closely associated with 
the HDL complex (Blatter et al. 1993) and there is accumulating evidence of its role 
in the prevention of LDL oxidation and atheroma formation (Mackness et al. 1993), 
hence preventive roles in cardiovascular disease.   PON1 degrades hydrogen peroxide 
via its peroxidase activity, hydrolyses phospholipid hydroperoxides and cholesterol 
ester hydroperoxides via its esterase activity and reduces lipid hydroperoxides to their 
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respective hydroxides (Aviram et al. 2000).  PON1 also improves reverse cholesterol 
transport to the liver and prevents HDL peroxidation (Aviram et al. 1998).  It may 
also have a role in protecting plasma membranes from free radical injury (Durrington 
et al. 2001) and degrades bioactive phospholipids like platelet-activating factor (PAF) 
(Rodrigo et al. 2001).  More recently, it was discovered that PON1 has lactonase 
activity and is involved in metabolism of drugs such as statins, spironolactone and 
glucocorticoid lactones (Billecke et al. 2000).  It also hydrolyses homocysteine 
thiolactone and prevents homocysteinylation of proteins, which is part of the 
atherogenesis process (Jakubowski 2000). 
 
PON1 is found in many animal species (La Du et al. 1993; La Du 1996; Nevin et al. 
1996) except birds, fish and insects (Mackness et al. 1996).  Earlier studies showed 
that birds were more sensitive than rats to OP toxicity since they have no to very low 
plasma PON1 activity (Brealey CB 1980).  Interestingly, recent studies suggest that 
birds have PON1-like genes which are about 70% identical to human PON1 (Primo-
Parmo et al. 1996).  Despite this, they have very low paraoxonase/arylesterase activity 
which is less than 1% of the average human levels. Rabbit and human sequence 
comparisons show almost 85% similarity at both protein and DNA levels, indicating 
the importance of the metabolic role of PON1.  In humans, serum PON1 is present in 
newborn and premature infants at half the level of that found in humans, but the levels 
reach adult levels quickly in just about one year after birth (Zech and Zurcher 1974; 
Mueller et al. 1983; Cole et al. 2003).  Older studies have claimed that PON1 levels 
are stable in adults and that there are no significant changes observed with age (Zech 
and Zurcher 1974; Playfer et al. 1977; Mueller et al. 1983).  However, newer ones 
show that there is a progressive decline in PON1 activity in elderly people 
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(Milochevitch and Khalil 2001; Jarvik et al. 2002; Seres et al. 2004).  PON1 is present 
at basal levels in the body and levels may change under different circumstances. This 
will be elaborated on in another section. 
 
Synthesis and structure 
PON1 is synthesised in the liver and some of it is secreted into the plasma where it 
associates with high density lipoprotein particles (La Du et al. 1993).  PON1 is also 
distributed into different tissues such as the kidney, heart, brain, lungs and small 
intestines (Primo-Parmo et al. 1996).   
 
Human PON1 was purified in 1991 (Gan et al. 1991), allowing the elucidation of the 
molecular mechanism of the PON1 activity polymorphism.   An interesting feature 
about PON1 synthesis is that it retains its signal sequence and only the initiator 
methionine is cleaved.  The mature PON1 protein contains three cysteine residues; 
two of which form a disulfide bridge (C42 and C353) (Sorenson et al. 1995). The 
third (C284) plays a role in the hydrolysis of substrates such as lactones, and in the 
prevention of low-density lipoprotein oxidation, but is not required in the hydrolysis 
of other substrates such as phenylacetate and paraoxon (Aviram et al. 1998).  PON1 
has two Ca2+ binding sites; there are two Ca2+ ions present in the central tunnel of the 
protein, one which acts as a stabiliser for the structure and the other which is involved 
in catalysis.  The former Ca2+ ion has a phosphate ion bound to it.  PON1 also has two 
N-linked glycosylation sites (Kuo and La Du 1995) and hydrophobic amino acid 
residues at the amino terminal end of the protein.  These residues account for its 
tendency to bind to other proteins and aggregate by itself (La Du et al. 1993). There 
are specific tryptophan, histidine, glutamic acid and aspartic acid residues that are 
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important components in the catalytic and calcium-binding sites of PON1 (Doorn et 
al. 1999; Josse et al. 1999; Josse et al. 2001).  
 
The recent elucidation of its crystal structure through a directly-evolved PON1 
variant, together with directed evolution studies, has allowed the study of PON1’s 
active site and its possible catalytic mechanisms (Harel et al. 2007).  However, the 
exact catalytic mechanism of OPs has not yet been discovered.  Harel et al. (2007) 
postulated that the lactonase and esterase functions of PONs are catalysed by a 
His115-His134 dyad, and that paraoxonase activity is probably catalysed by different 
residues.  Figure 4 shows the crystallised structure of PON1. 
 
Figure 4. Overall structure of PON1. (a) View of the crystallised structure of PON1 from 
above. Harel et al. discovered that PON1 was made up of a six-bladed -propeller (A-D).  The N and 
C termini and the two calcium atoms in the central tunnel of the propeller (Ca1, green; Ca2, red) are 
shown. (b) A side view of the propeller, including the three helices at the top of the propeller (H1−H3). 
(Adapted from Harel et al. 2007) 
 
Measurement of activity 
PON1 activity can be measured using serum isolated from heparin-collected blood.  
Measurements are carried out using a spectrophotometer or equivalent instrument. 
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Hydrolysis of paraoxon produces p-nitrophenol, monitored at 405 nm, while 
hydrolysis of diazoxon produces 2-isopropyl-4-methyl-6-hydroxypyrimidine, 
monitored at 270 nm.    After determining initial rates of substrate hydrolysis, rates of 
diazoxon hydrolysis (y-axis) are plotted against the rates of paraoxon hydrolysis (x-
axis).  PON1 activity is measured in the presence of 1M NaCl in order to stimulate 
activity. Measurement also has to be done at pH 8.5 since at higher pH values, 
albumin-associated esterase activity will interfere with PON1 activity (Erdos and 
Boggs 1961).  The assay has to be carried out in the presence of calcium as calcium 
has been shown to be important in maintaining the structural organisation of the 
PON1 protein as well as in regulation of its catalytic function (Kuo and Du 1998). 
 
PON1 status 
The method described above separates individuals into the three phenotypes of 
PON1Q192R activity – PON1192QQ, PON1192QR and PON1192RR (to be discussed in 
greater detail in the next chapter).  The resulting plot would be one like shown in 
Figure 5.  Here, the individual PON1 status of the sample is clustered according to 
phenotype and as can be seen, the functional position of the PON1Q192R genotype is 
accurately inferred.  Within each genotype, PON1 activities provide information of 
the levels of PON1 in the plasma of a particular individual in that genotype group.  
This information is crucial in assessing an individual’s sensitivity to a specific OP. 
For example, even though two people might have the same activity towards paraoxon, 
one person could be better able to detoxify diazoxon than the other – hence suggesting 
that the latter would be more susceptible to diazoxon-containing OP pesticides.  
Genotyping each individual’s DNA would be able to verify the PON1 phenotype at 
position 192 (Richter et al. 2004).  Often though, with very few exceptions (Jarvik et 
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al. 2003), this functional genomic analysis of PON1 status is very reliable and does 
not require confirmation (Jarvik et al. 2000).  An example of possible discordance 
would be if an individual genotypes as a PON1192Q/R heterozygote but has a PON1 
status that indicates a PON1Q192 or PON1R192 homozygote (i.e. QQ or RR).  A 
probable reason for this would be that one of the alleles could be nonfunctional. This 
emphasises the advantage of analysing PON1 status over straight genotyping.  Rapid 
high-throughput methods are currently available to enable quick measurements of 
PON1 activity in large numbers e.g. assays down-scaled to fit 96-well microplates and 
the OXItek Arylesterase/Paraoxonase Assay Kit (ZeptoMetrix Corporation, USA). 
 
 
Figure 5.  Determination of PON1 status.  Plotting diazoxonase vs. paraoxonase activities 
breaks the population into three groups, individuals homozygous at amino acid position 192 for Q 
(open circles) or R (open triangles) and heterozygotes (closed squares) which have been confirmed by 
PCR.  In addition, this analysis of hydrolysis rates provides the PON1 phenotype (PON1 level) for each 
individual in the population.  The arrows point to four discordant subjects – where genotype and 
enzyme activity analysis did not match.  Further sequencing of their genes showed mutations in one of 
their alleles, resulting only in one alloform of PON1 in their serum. (Adapted from Jarvik et al. 2003) 
 
Besides being able to hydrolyse paraoxon and diazoxon, PON1 is also able to 
hydrolyse other similar OP compounds, aromatic carboxylic acid esters and 
carbamates (La Du 1992).  This includes phenylacetate which measures PON1’s 
 17
arylesterase capabilities, toxic oxon forms of chlorpyrifos and the nerve agents sarin 
and soman (Smolen et al. 1991).  Recently, it has been hypothesised that lactonase 
activity instead of arylesterase or organophosphate activity could be a common 
feature of PON1 proteins (Draganov et al. 2000). This came about after the 
characterisation of the hydrolytic activity of PON1 on 30 lactones, thiolactones and 
cyclic carbonate esters (Billecke et al. 2000; Draganov et al. 2000; Jakubowski 2000). 
It is common convention to use the substrate name to define PON1 activity e.g. 
“paraoxonase” if the substrate was paraoxon, “diazoxonase” if the substrate was 
diazoxon and “arylesterase activity” if the substrate was phenylacetate. 
 
Measurement of concentration 
Serum PON1 concentration can be measured using a competitive enzyme-linked 
immunosorbent assay (ELISA) using a monoclonal antibody (Blatter Garin et al. 
1994) or by sandwich ELISA using two monoclonal antibodies.  PON1 concentration 
has been shown to be positively associated with both serum arylesterase activity and 
serum paraoxonase activity (Kujiraoka et al. 2000) . Measuring PON1 concentration 
is useful as it provides the vital complement to enzyme-activity measurements and 
allows a more comprehensive picture of PON1 in different clinical and 
epidemiological settings. 
 
Role of PON1 in detoxifying organophosphates 
OPs are A-esters that can be used as pesticides since A-esterases are not found in the 
serum of lower vertebrates.  The major route of detoxification of OPs to less toxic 
metabolites is via hydrolysis by serum and hepatic A-esterases.  Figure 2 above 
depicts the metabolic pathway of OP detoxification.  The importance of detoxification 
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by PON1 has been shown in animal models from very early investigations e.g. as 
mentioned above where birds displayed higher sensitivity to OPs.  There have been 
studies in rodents where injection of PON1 protects against OP poisoning (Costa et al. 
1990; Li et al. 1995).  Conversely, PON1-knockout mice have been shown to be 
susceptible to OP toxicity (Shih et al. 1998). 
 
Interestingly, PON1 is also able to protect against toxicity of the parent compound 
chlorpyrifos when administered before or even after OP exposure (Li et al. 1995).  
Protection of mice against chlorpyrifos toxicity was also possible via recombinant 
human PON1 expressed in an adenoviral vector (Cowan et al. 2001).  Subsequent 
studies showed the capacity of recombinant naked DNA (pcDNA/PON1) to protect 
mice from acute soman toxicity (Fu et al. 2005).  On the whole, these studies reveal 
that decreasing the toxicity of certain OPs is possible through artificially enhancing 
serum PON1 levels. 
 
The role of PON1 in detoxifying OPs has been further explored via experiments in 
genetically modified mice.  PON1 knockouts have drastically increased sensitivity to 
chlorpyrifos-oxon and diazoxon toxicity, with a small increase in sensitivity to the 
parent compounds, chlorpyrifos and diazinon respectively (Shih et al. 1998; Li et al. 
2000).  Li et al. (2000) showed that restoring plasma PON1 by administering purified 
human PON1 to PON1 knockout mice enabled protection against chlorpyrifos-oxon 
and diazoxon.  PON1Q192 and PON1R192 were able to provide equal protection 
against diazoxon, while PON1R192 provided 50% more protection against 
chlorpyrifos-oxon.  The latter findings were corroborated in a later study where 
murine PON1 was replaced with either hPON1Q192 or hPON1R192 in a transgenic 
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mouse model.  Although PON1 levels were similar in both mouse lines, mice which 
expressed hPON1R192 were more resilient against chlorpyrifos-oxon toxicity (Cole 
et al. 2005).  These results are also found in in vitro studies of PON1 activity towards 
chlorpyrifos-oxon or diazoxon.  Human PON1R192 has double the efficiency of 
PON1Q192 in catalysing chlorpyrifos-oxon but both alloforms hydrolyse diazoxon to 
a similar extent (Li et al. 2000).  Surprisingly, it was found that PON1 knockout mice 
were not more sensitive than wild-type mice to paraoxon toxicity even though there 
was no PON1 activity in liver and plasma.  Moreover, administration of human PON1 
did not restore protection against paraoxon toxicity.  In vitro analysis was able to 
explain these results.  Under physiological conditions in vitro, PON1R192 is eight 
times more efficient than PON1Q192 at hydrolysing paraoxon. However when 
compared to catalytic efficiencies towards chlorpyrifos-oxon and diazoxon, the 
overall catalytic efficiency was still very low.  This suggests that PON1 is probably 
not efficient at hydrolysing paraoxon at low concentrations hence, as previously 
suggested, paraoxon degradation in vivo might not be efficient (Pond et al. 1995). 
 
The studies above show that PON1 plays an important role in the modulation of 
toxicity of some, but not all, OPs.  These in vivo substrates of PON1 are detoxified 
according to levels of PON1 hence PON1 levels are important in modulating OP 
toxicity.  It is tempting to extrapolate findings from animal models to humans because 
of the results obtained in mice expressing human hPON1Q192 or hPON1R192.  
However, it is still important to determine the sensitivity of humans to OP toxicity 
more directly so that we can have more conclusive information but unfortunately such 
studies are still lacking.  In recent years, a variety of circumstances in the Middle 
East, the United Kingdom and Japan have led to the need for investigations on the 
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role of PON1 in OP toxicity in humans.  These studies which have been mentioned 
elsewhere – e.g. sarin exposure in the Tokyo subway in a terrorist attack, possible 
sarin (and/or other OPs) exposure in British and American veterans of the 1991 Gulf 
War, and sheep dippers exposed to diazinon in the United Kingdom – suggest a role 
of PON1 in modulating OP sensitivity in humans but do not allow concrete 
conclusions to be made.  Thus, more well-designed human studies are required to 
directly assess this issue to allow proper documentation of the role of PON1 activity 
in conferring protection to different types of OPs. 
 
PON1 Gene 
PON gene family and structure of PON1 
The human PON1 gene has a moderate gene size of 26.8 kilobases. It lies at 
chromosome position 7q21.3 and contains an open reading frame which encodes for 
355 amino acids.  PON1 is part of a multigene family that consists of highly 
homologous genes PON2 and PON3 (Primo-Parmo et al. 1996; Mochizuki et al. 
1998).  All three genes are located on the same chromosome (Figure 6A).  PON2 and 
PON3 are about 60-70% identical to PON1.  The main feature that distinguishes 
PON1 from the other PON genes is that it has an extra three nucleotide residues in 
exon 4 which codes for amino acid 105 (Primo-Parmo et al. 1996).  The similarities 
between the three genes strongly suggest that they arose from gene duplication.  It has 
been established that the coding region of human PON1 consists of nine exons 
(Clendenning et al. 1996).  It has an Alu sequence in intron 8 and a polymorphic CA 
dinucleotide repeat, 46 nucleotides long, in intron 4 (Primo-Parmo et al. 1996).  There 
is some inter-individual variation in the polyadenylation signal of the gene which has 
been postulated to affect differences in enzyme levels (Hassett et al. 1991).  Figure 6B 
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shows the gene structure of PON1 and the location of its known polymorphisms (not 
to scale). 
 
       
 
Figure 6.  PON gene structure. (A) PON gene family consisting of PON1, PON2 and PON3 
located close to each other on chromosome 7, bands q21–q 22. (B) The PON1 gene (not to scale) and 
its commonly studied polymorphisms.  The figure shows the locations of five 5’ regulatory region 
polymorphisms, nine exons (shown as bold lines and including two coding region polymorphisms), a 
variable length CA-repeat in the fourth intron and four 3’ untranslated region polymorphisms. (Adapted 
from Furlong et al. 2002) 
 
PON1 polymorphisms 
PON1 contains several polymorphic sites i.e. two or more alleles exist at significant 
frequencies in the population.  A particular form of polymorphism is the single 
nucleotide polymorphism (SNP) which is defined as the specific difference in one 
base at a defined location of an individual’s DNA.  The coding region of the PON1 
gene has two SNPs; one at position 55 where a methionine (M) is substituted with 
leucine (L), and another at position 192 where arginine (R) is substituted for 
glutamine (Q) (Figure 6B) (Hassett et al. 1991; Adkins et al. 1993; Humbert et al. 
1993).  Employing the method of polymerase chain reaction (PCR) initially followed 
by restriction enzyme digest proposed by Humbert et al (1993), both these 
polymorphisms can be easily detected (Figure 7).  Indeed, there have been numerous 














populations using the restriction fragment length polymorphism (RFLP) method 
described above.  The different allelic forms of PON1 are sometimes called isozymes 

















Cut with Nla III 
Figure 7.  Restriction enzyme analysis of the PON1 Q192R (top) and L55M 
(bottom) genotypes.  The amplified DNA fragment will be cut with restriction enzyme Alw I if the 
segment encodes the amino acid arginine at position 192 but will not be cut if glutamine is encoded at 
this position.  Likewise, the amplified segment encoding methionine at position 55 will be cut by 
restriction enzyme Nla III but will not be cut if leucine is encoded. 
 
Coding region polymorphisms: Q192R and L55M 
Q192R polymorphism 
The idea that PON1 activity is genetically determined had been proposed as early as 
1973 (Geldmacher-von Mallinck et al. 1973).  Not long after, it was confirmed that 
there were three PON1 genotypes which differed with regards to activity towards 
paraoxon (Playfer et al. 1976).  Since then, the Q192R polymorphism has become the 
most studied PON1 polymorphism.  Further investigations found that the isozyme 
with R at position 192 was responsible for the higher activity of PON1 towards 
paraoxon (sometimes referred to as the B-type allozyme) while the isozyme with Q at 
this position was responsible for the lower activity (A-type allozyme) (Adkins et al. 
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1993; Humbert et al. 1993; Primo-Parmo et al. 1996).  This was also true for PON1 
activity against chlorpyrifos oxon (Li et al. 2000). The Q192R polymorphism has 
significant effects on the catalytic activity of PON1, in a substrate-dependent manner.  
This is because in in vitro assays, it was found that the PON1Q192 isoform 




The second polymorphism in the coding region of PON1 is L55M (Humbert et al. 
1993).  While the Q192R polymorphism has a role in catalytic efficiency of PON1, 
the L55M polymorphism has not been found to be associated with catalytic efficiency 
(Adkins et al. 1993; Humbert et al. 1993; Davies et al. 1996; Li et al. 2000).  Instead, 
this polymorphism has been associated with differences in PON1 mRNA and plasma 
PON1 levels, with PON1M55 individuals having lower PON1 levels on average 
(Garin et al. 1997; Leviev et al. 1997; Mackness et al. 1998; Brophy et al. 2000).  This 
has been explained by the fact that PON1M55 is in strong linkage disequilibrium with 
promoter polymorphisms (Brophy et al. 2001).  Furthermore, it has also been 
suggested that the PON1M55 isoform is less stable than the PON1L55 isoform 
(Leviev et al. 2001).   The variation in PON1 concentration partly accounts for the 
almost 40-fold difference in PON1 activity among individuals, and an almost 13-fold 
difference in activity within a particular genotypic class e.g. individuals who are 





Promoter region polymorphisms 
Other polymorphisms have been found in the non-coding region of the PON1 gene 
(Leviev and James 2000; Suehiro et al. 2000; Brophy et al. 2001; Brophy et al. 2001).  
These polymorphisms are at positions 108 (C/T), 126 (G/C), 162 (A/G), 832 (G/A), 
and 909 (C/G).  These polymorphisms are common in the population and at least 
three of them, namely those at positions 108, 162 and 909, have an influence on 
promoter activity which results in up to two-fold difference in gene expression 
(Brophy et al. 2001).  The position 108 polymorphism appears to have the most 
significant effects, contributing 22.4% to the variation in PON1 expression, with the 
thymidine for cytosine change (C108) having higher concentrations of plasma PON1.  
This position could also be a transcription activation factor binding site.  The 
polymorphism at position 162 contributes a small amount (2.4%) to plasma PON1 
levels (Brophy et al. 2001).  The polymorphisms at the 3’ region of the PON1 gene 




The coding region polymorphisms Q192R and L55M are in linkage disequilibrium 
(p<0.001).  A few studies have shown that 98% of the PON1R192 alleles have the L 
allele at position 55 (Brophy et al. 2001).  This relationship allows the concurrent 
presence of alleles which code for high paraoxonase activity (Garin et al. 1997).  
Because of this linkage, PON1 L55M and Q192R alleles only form three PON1 
haplotypes instead of four within the Caucasian population.  These are L55/Q192, 
L55/R192 and M55/Q192 (Cascorbi et al. 1999; Malin et al. 2001). 
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Interestingly, the coding region polymorphism L55M is in strong linkage 
disequilibrium with the promoter region polymorphisms at positions 108, 162 and 
909.  Despite this, the observed associations between the L55M polymorphism and 
PON1 concentrations cannot be entirely explained by these promoter region 
polymorphisms (Leviev et al. 2001). 
 
As a result of the linkage between the polymorphisms mentioned above, the presence 
of specific alleles leads to considerable differences in PON1 activity towards not only 
substrates considered discriminatory (paraoxon) but also towards substrates 
considered non-discriminatory (phenylacetate).  This means that for a “non-
polymorphic” substrate like phenylacetate, only the amount of enzyme present is 
important, whereas for a polymorphic substrate such as paraoxon, both the alleles 
present and the amount of protein made for each are crucial. 
 
PON1 polymorphisms and ethnic distribution 
The PON1 polymorphisms have been studied extensively for their distributions 
among various populations.  It has been shown numerous times that different ethnic 
groups possess differing levels of certain PON1 polymorphisms.  As early as 1976, 
Playfer et al. discovered the existence of a spectrum of differences in the distribution 
of PON1 polymorphisms across different populations.  It was found that the British 
and Indian populations had bimodal distributions of PON1 activity while the African, 
Chinese and Malay populations had differing distributions which were not bimodal.  
Palestinians, Turks, Iranians, Sri Lankans and Europeans have a larger group of low 
PON1 activity (Diepgen and Geldmacher-von Mallinckrodt 1986).  Canadians (Carro-
Ciampi et al. 1981), Koreans, Japanese, Indonesians, Nigerians, Zimbabweans and 
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Zambians (Geldmacher-von and Diepgen 1988) have low proportions of the lower 
activity group.  These data suggest that allelic frequency of PON1 varies to a great 
degree across different ethnicities.   
 
More recent studies have established the different gene frequencies in different 
ethnicities. For example,  Caucasians of Northern European origin have been found to 
have PON1Q192 gene frequencies of 0.75 while some Asian populations have 
frequencies of only 0.31 (Costa et al. 2005).  As mentioned above, the PON1R192 
allele hydrolyses paraoxon more rapidly than the PON1Q192 isoform but the activity 
is reversed in the hydrolysis of toxic nerve agents such as sarin.  In 1995, an attack on 
the Tokyo subway using sarin caused the death of 10 Japanese. Upon investigation of 
the alleles present in a Japanese sample, it was found that the PON1R192 
polymorphism was more dominant in the Japanese population, with an allele 
frequency of 0.66 (Yamasaki et al. 1997).  This was found to be relatively higher than 
that in American, French and Finnish populations previously investigated. The higher 
efficiency of PON1R192 in the Japanese could mean that they would be more 
protected against paraoxon-related pesticide poisoning, as suggested by Humbert et al 
(Humbert et al. 1993). However, the same allele probably aggravated the tragedy in 
the Tokyo subway incident since this isoform has a slower hydrolysis rate for sarin 
(Davies et al. 1996). 
 
Chinese 
For the purpose of this project, we focused on reviewing the studies on PON1 
polymorphisms relevant to our local population – namely Chinese, Malays and 
Indians.   In a study conducted by Sanghera et al. (1997) it was found that Chinese 
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living in Singapore had a PON1R192 frequency of 0.58.  Among them, the QR 
genotype was the most common (50%), followed by RR (33%) and QQ (17%).  As an 
extension to this study, the group went on to study the distribution of the PON1 
polymorphism at codon position 55 (Sanghera et al. 1998).  The frequency of the 
PON1M55 allele was only 0.036.  The PON1M55 allele is so rare in Chinese that 
none of the Chinese subjects had the MM genotype in this sample.  The LL genotype 
was the most common (92.8%), followed by LM (7.2%).  This and several other 
studies involving Chinese from different parts of China confirm that the R allele is 
dominant in people with Chinese ethnicity, with a frequency between 0.54-0.63 
(Padungtod et al. 1999; Zhou et al. 2000; Ma et al. 2003; Zhang et al. 2006).  
Similarities in allele frequencies in the PON1L55M polymorphism were also seen 
among different Chinese populations, where the PON1L55 allele was more common 
in the population, with frequencies as high as 0.97 (Wang et al. 2003; Zhang et al. 
2006).  From these figures, we would assume that in the event of OP poisoning, the 
Chinese would be more protected against paraoxon-containing pesticides since they 
have the allele with higher catalytic activity towards paraoxon (R), as well as the 
allele which confers higher plasma PON1 levels (L). 
 
Malays 
The only study on Malays that has been done so far was from a population of Malays 
from Malaysia, where it was found that the L allele frequency was 0.94 and the R 
allele frequency 0.59  (Poh and Muniandy 2007).  The QR genotype was the most 
common (43%), followed by RR (33%) and QQ (24%).  For the PON1L55M 
polymorphism, the LL genotype was the most common (85%) followed by LM (13%) 
and MM (2%).  Interestingly, the allele frequencies and general distribution of the 
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individual genotypes in the Malays are somewhat close to those of the ethnic Chinese 
described above.  This similarity could be explained by the fact that Malays and 
Chinese are both anthropologically classified as Mongoloids, demonstrating that 
ethnicity (and perhaps common ancestry) influences PON1 genotype. 
 
Indians 
In the same study mentioned above, Sanghera et al. (1997) also found that Indians in 
Singapore (who are mainly made up of Dravidians from south India) had an R allele 
frequency of 0.33.  The QQ genotype was the most common (47%), followed by QR 
(40%) and RR (13%).  The Indians had significantly higher frequency of the M allele 
(0.20 vs. 0.036, p<0.0001) compared to the Chinese mentioned above.  The LL 
genotype was the most common (65%), followed by LM (29.5%) and MM (5.5%).  A 
study among a group of Indians from India had similar results to the Indians in 
Singapore (Pati and Pati 1998).  Here, the Q allele was also found to be dominant, 
with the frequency of the R allele being only 0.17. The QQ genotype was also the 
most common (75%), followed by QR (15%) and RR (10%). 
 
PON1 and Organophosphate Toxicity 
PON1 levels and polymorphisms 
Plasma levels of PON1 vary widely between and within populations and these 
distinctions can be easily seen even using the simple assays described previously.  
PON1 levels have been estimated to differ by almost 40 times within the same 
population (Richter and Furlong 1999); within a Caucasoid population, it was shown 
that there was an 11-fold difference between the highest and lowest PON1 activity 
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values (Furlong et al. 1988).  Even among individuals of the same genotype, the 
variation can be up to 13 times as seen in a Hispanic population (Davies et al. 1996). 
 
Since having particular polymorphisms and hence different levels of PON1 activity 
increases susceptibility to OP toxicity, it is important to establish the distribution 
profile of important PON1 polymorphisms in distinct populations.  This is especially 
vital for occupationally exposed workers who are at higher risk for OP toxicity.  The 
health effects they face have been documented in several scenarios.  For instance, 
farmers reporting ill health which they attributed to exposure to diazinon-containing 
sheep dip were more likely to have higher frequencies of the PON1R192 and 
PON1L55 alleles than their counterparts who perceived themselves to be in good 
health. Since these polymorphisms have been shown to hydrolyse diazoxon at a 
slower rate, their ill health may be attributed to their lower ability to detoxify 
diazoxon (Cherry et al. 2002). In a study on fruit farm workers in South Africa, 
presence of the PON1Q192 allele was one of the predictors of chronic toxicity to 
paraoxon (Lee et al. 2003). Furthermore, the prevalence of chronic toxicity was 
higher among workers with the QQ/QR genotype compared to those with the RR 
genotype.  In another study, it was found that workers with the RR genotype were 
more susceptible to effects of OP toxicity as seen from the reduction in their sperm 
DNA integrity and semen quality in traditional farmers from southeastern Mexico 
(Pérez-Herrera et al. 2008).  In addition, it has also been found that Gulf War veterans 
who were more likely to report that they suffered from symptoms of Gulf War 
Syndrome were those who possessed the R allele, supporting the notion that the R 
allele confers less protection against nerve gases (Haley et al. 1999).  As seen from 
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these studies, it is obvious that different PON1 genotypes affect response to OP 
exposure differently. 
 
Environmental factors affecting PON1 concentration and activity 
Apart from the genetic component of PON1 phenotypic variation, there are exogenous 
factors which modulate PON1 concentration and activity.  PON1 may be upregulated 
under certain conditions such as exercise and upon administration of some drugs 
(Tomas et al. 2002).  Levels of PON1 activity have been reported to be different 
between sexes in human and animal studies with females showing higher mean basal 
activity levels (Mueller et al. 1983; Kleemola et al. 2002; Rainwater et al. 2005; 
Winnier et al. 2007).  Environmental factors such as menopause and increased 
contraceptive use reduce PON1 levels, also supporting sex-specific effects on PON1 
activity. 
 
Although PON1 activity is dependent on calcium, other cations such as copper, zinc, 
mercury, cobalt, manganese and lead, to name a few, been shown to inhibit its activity 
in vitro (Gonzalvo et al. 1997; Debord et al. 2003; Pla et al. 2007).  Despite this, in 
vivo exposure of mice to metals like dietary iron, cadmium and methylmercury did 
not alter PON1 activity in plasma and liver (Cole et al. 2002). 
 
The effects of pharmaceutical compounds on PON1 activity have been largely studied 
via focus on lipid-lowering drugs.  Contrasting results have been found in both in 
vitro and in vivo studies in mice and humans.  While some studies found an increase 
in serum PON1 activity in patients treated with simvastatin and other statins, 
fenofibrate and gemfibrozil (Balogh et al. 2001; Jarvik et al. 2002; Deakin et al. 2003; 
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Paragh et al. 2003), other studies did not find any changes when patients were treated 
with gemfibrozil, bezafibrate (Durrington et al. 1998) and ciprofibrate (Turay et al. 
2000).  Aspirin users were reported to have significantly increased plasma PON1 
activity and concentration (Blatter-Garin et al. 2003).  Another anti-inflammatory 
glucocorticoid dexamethasone resulted in an eight-fold increase in PON1 mRNA in a 
mouse hepatoma cell line (Hepa cells) and in mice in vivo (bin Ali et al. 2003).  
Several findings suggest that PON1 is not easily modulated by classical enzyme 
inducers such as phenobarbital, β-naphtoflavone or 3-methylcholantrene,  although it 
is argued that a modulator like phenobarbital may be able to impede the secretion of 
PON1 from the liver through some unknown mechanism (Vitarius et al. 1995). 
 
Besides exogenous compounds, lifestyle factors such as smoking and alcohol 
consumption and their respective relationships with PON1 levels have been studied.  
Smoking has been proven to inhibit PON1 activity (James et al. 2000; Jarvik et al. 
2002; Ferre et al. 2003; Senti et al. 2003).  The effect of cigarette smoke on PON1 
activity has been suggested to be direct since there is a reversal of effects within a 
fairly short time (Nishio and Watanabe 1997; James et al. 2000).  In light of the recent 
perception that reasonable doses of ethanol has a protective role in cardiovascular 
disease, studies have been carried out to see if there is a link between alcohol intake 
and PON1 activity.  Although a few human studies showed no relationship between 
alcohol consumption and PON1 activity (Ferre et al. 2003; Sarandol et al. 2003; 
Vincent-Viry et al. 2003), several studies in both animals and humans showed that 
lower quantities of ethanol enhanced PON1 activity and levels while higher quantities 
caused reductions (Van Der Gaag et al. 1999; Sierksma et al. 2002; Rao et al. 2003).  
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This regulation did not appear to be affected by PON1 polymorphisms (Rao et al. 
2003). 
 
Dietary factors such as a fat-rich diet also seem to modulate PON1 activity in a 
manner that depends on the composition of phospholipids (Tomas et al. 2001; 
Wallace et al. 2001).  Polyenoic fatty acids (e.g. linoleic acid) reduced PON1 activity 
while monoenoic acids (e.g. oleic acid) were effectively able to stabilise PON1 and 
protect it from oxidative inactivation (Nguyen and Sok 2003).   Various studies in 
vitro (Aviram et al. 1999), in animals (Hayek et al. 1997; Kaplan et al. 2001) and 
humans (Aviram et al. 2000) point towards the direction that PON1 activity is 
increased by antioxidants.  However, some conflicting results have been found where 
Vitamin C and E was either positively correlated (Jarvik et al. 2002), negatively 
correlated (Kleemola et al. 2002; Rosenblat et al. 2003), or had no association (Ferre 
et al. 2003) with PON1 activity.  Further investigations would thus be needed to 
verify these contradictory effects of dietary antioxidants on PON1 levels and activity. 
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PARAOXONASE (PON1) POLYMORPHISMS AS A 
BIOMARKER OF SUSCEPTIBILITY TO 
ORGANOPHOSPHATE TOXICITY AMONG A COHORT 
OF SINGAPOREAN WORKERS 
 
AIMS OF THE STUDY 
Cholinesterase levels have been shown in some, but not all, studies to be reduced in 
the presence of OP exposure.  However, most of these studies have been conducted in 
the west while few exist in Asia.  To the best of our knowledge, there have been no 
reports on pesticide exposure and health symptoms in the local population.   
 
Our main objective was to study whether pest control workers in Singapore exposed 
to OP-containing pesticides were in danger of toxicity, and if PON1 polymorphisms 
had a role to play in susceptibility towards OP toxicity.  This was achieved by 
assessing the levels of RBC AChE and serum PChE as biomarkers of OP toxicity, and 
determining whether there were any associations between these biomarkers and 
exposure status, PON1 status and PON1 polymorphisms.  We also studied whether 
these indices were affected by ethnicity, and looked at the extent of use of personal 
protective equipment (PPE) among pesticide workers since this may have an effect on 
exposure outcome. 
 
The specific aims of this study were to: 
1. Analyse whether serum PChE and RBC AChE levels were different between the 
exposed and unexposed groups. 
2. Study the extent of PPE usage employed by workers during pest management 
activities. 
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3. Study the interaction between factors such as exposure duration, alcohol 
consumption, smoking status, BMI and age in relation to serum PChE and RBC 
AChE levels. 
4. Analyse PON1 activity towards paraoxon and diazoxon and assess whether 
activity levels differed between exposed and unexposed workers. 
5. Determine the genetic frequencies of the common PON1 polymorphisms and 
study any differences in distribution between the two groups. 
6. Characterise the distribution of common PON1 polymorphisms in the local 
population and study the distribution patterns among the different ethnic groups. 
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PARTICIPANTS AND METHODS 
Study Population 
The design of the study was cross-sectional in nature. The study was approved by the 
National University of Singapore Institutional Review Board. Informed consent was 
obtained from each worker before the commencement of the study. 
 
The study population consisted of two populations of adult male workers in Singapore 
who were recruited through convenience sampling.  The unexposed group was 
initially made up of 96 male and female workers from a lead stabiliser factory in 
Singapore but since all the pesticide workers were male, we only included male 
controls in our study, leaving a total of 91 workers.  None of the unexposed group 
workers were exposed to organophosphorous pesticides.  The exposed group was 
comprised of 105 workers from various pest control companies under the Singapore 
Pest Management Association (SPMA). We obtained a list of pest control workers 
from SPMA and recruited them into the study during their routine medical checkup 
which they are required to attend half yearly. All workers from the production line as 
well as in the division of management and quality control were recruited into this 
study. Of the 105 pest control workers, 104 were occupationally exposed to OPs and 
the remaining one was not directly exposed to OPs (management division). One 
worker was unable to give blood hence the final number of exposed workers was 103.  
Response rates were calculated based on number of participants recruited vs. total 
number of workers who attended the medical examinations (i.e. workers included in 
the list we obtained from SPMA). The response rates in the exposed and unexposed 
groups were 98.1% and 90.5% respectively.  The resulting total of 194 workers was 
comprised of the three major ethnic groups in Singapore, namely Chinese, Indian and 
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Malay.  Signed consent was obtained from each worker before any data, including 
biological specimens, were collected. 
 
Questionnaire 
All data was collected by trained research assistants.  A structured questionnaire 
including information such as age, detailed occupational history, and current and 
previous smoking habits was administered to all participating workers with the help of 
the research assistants.  Alcohol intake was also documented carefully as it could 
confound the findings.  Each worker was also interviewed for neurological symptoms 
of OP exposure.  The exposed workers were given an additional questionnaire which 
included information about exposure duration, types of pesticides used, and period 
and frequency of use.  Exposed workers were also asked about usage of PPE during 
pesticide application e.g. mask, gloves, cap, boots and coverall.  According to the 
NEA, the minimum requirements for sufficient PPE should consist of gloves, 
respirator, goggles, dust coat, safety boots, helmet and ear muffler (National 
Environmental Agency 2002). Those with nervous system and hepatobiliary diseases 
were to be excluded; however, none of the workers had such conditions.  A sample of 




We collected 10 mL of blood from each worker during the medical examination for 
subsequent analysis. We obtained blood samples by venipuncture with lead-free 
disposable syringes and stored the samples in heparinised lead-free polypropylene 
tubes. Serum and heparin plasma were prepared by lowspeed centrifugation.  Serum, 
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plasma and buffy coat were separated into 0.5 mL aliquots within 1 h of blood 
collection and stored at -80 °C until analysis. 
 
Cholinesterase measurements 
Serum PChE enzyme activity was measured spectrophotometrically according to the 
Knedel and Bottger method (Knedel and Bottger 1967) using the ADVIA chemistry 
system (Bayer HealthCare LLC, USA). This colorimetric method uses S-butyryl-
thiocholiniodide as a substrate for cholinesterase hydrolysis into butyrate and 
thiocholine.  The latter reduces 5,5'-dithiobis(2-nitrobenzoic acid) to 5-thio-2-
nitrobenzoate.  The increase in absorbance at 410 nm is comparative to the 
cholinesterase activity in the sample.  RBC AChE activity was measured 
spectrophotometrically according to the Ellman procedure (Ellman et al. 1961). All 
measurements were made within the same day as sample collection. 
 
PON1 activity measurements 
PON1 activity towards paraoxon was measured after the reaction of paraoxon 
hydrolysis into p-nitrophenol and diethylphosphate catalysed by the enzyme.  Levels 
of paraoxonase (herewith referred to as POX) activity was determined from the initial 
velocity of p-nitrophenol production (subtracting spontaneous paraoxon hydrolysis) at 
37 °C and recorded at 405 nm by a Shimadzu UV/Vis recording spectrophotometer 
(Shimadzu Corporation, Japan). The assays contained 90 mM Tris-Hcl (at pH 8.5), 
3.6 mM NaCl, 1.9 mM CaCl2, 5 mM paraoxon in a volume of 1 mL and were initiated 
by the addition of 50 µL of serum (adapted from Tomas et al. 2000). Enzyme activity 
was calculated with a molar extinction coefficient of 18053 M-1 cm-1. One unit of 
paraoxonase activity produced 1 nmol of p-nitrophenol per minute. 
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PON1 activity towards diazoxon (i.e. diazoxonase activity, herewith referred to as 
DZO) was also determined by continuous spectrophotometric assays after the 
hydrolysis of diazoxon into 2-isopropyl-6-methyl-4-hydroxypyimidine (IMHP) and 
diethyl phosphoric acid. Appearance of IMHP was continuously monitored at 270 nm.  
The assay contained 0.1 M Tris-HCl (at pH 8.5), 2.0 mM NaCl, 2.0 mM CaCl2 and 
500 µM diazoxon in a volume of 1 mL and were initiated by the addition of 10 µL of 
serum at 37 °C (adapted from Richter and Furlong 1999).  Enzyme activity was 
calculated with a molar extinction coefficient of 3000 M-1 cm-1. One unit of DZO 
activity corresponded to 1 µmol of IMHP produced per minute. Paraoxonase and 
diazoxonase activities are expressed as units (U) per litre (L) serum, where one U is 1 
μmol substrate hydrolysed per minute. 
 
Reaction mixtures were prepared daily and the same pool of human control sera (each 
aliquot thawed just before beginning the assay) was used as an internal control.  A 
blank determination of basal assay mixture without serum was made to account for 
any spontaneous hydrolysis of diluted paraoxon/diazoxon solutions. We measured in 
triplicate at least one aliquot of serum pool for every 20 samples. The serum pool was 
used to correct for interassay variations. In addition, each measurement was repeated 
and the average of two readings was taken for calculation of PON1 activity.  Intra and 
inter-assay coefficients of variation were less than 6% and 2% respectively. 
 
PON1 polymorphism screening 
Buffy coats were separated and stored at -80 °C until DNA extraction. DNA was 
extracted from the buffy coats using our own laboratory’s established salting-out 
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method and was used as starting material to amplify the target region in the PON1 
gene by the polymerase chain reaction (PCR). 
 
The DNA fragment containing the codon 192 polymorphism was amplified using 
forward 5'-  TAT TGT TGC TGT GGG ACC TG -3' and reverse 5'- CAA ATC CTT 
CTG CCA CCA CT -3' primers. Each PCR reaction was performed in a final volume 
of 25 µL, which included 10 ng of pure genomic DNA, 1.0 µM each primer, 200 µM 
each dNTP, 1  Taq buffer, 1.5 mM MgCl2, and 1.0 U of Taq DNA polymerase (all 
from Promega Corp., USA), and topped up to the required volume with sterile 
distilled water.  The amplification cycles were performed on the PTC-100 MJ 
Thermal Cycler (PerkinElmer Inc., USA) and optimised to ensure specific 
amplification of the products of interest. After the DNA was denatured for 3 minutes 
at 95°C, the reaction mixture was subjected to 30 cycles of denaturation for 30 
seconds at 95°C, 30 seconds of annealing at 61°C, and 30 seconds of extension at 
72°C. We used the restriction fragment length polymorphism (RFLP) method to 
locate the site of mutation. Digestion was carried out by the Alw I restriction enzyme 
(New England Biolabs, USA) and the fragments were determined on a 4.0% agarose 
gel (Seakem agarose; Cambrex North Brunswick Inc., USA) and visualised on the 
Biorad Gel Doc 2000 system (BioRad Laboratories, USA).  After digestion, the Q 
allele was identified by a non-digested 155-bp fragment while the R allele was 
identified by 61-bp and 94-bp fragments. 
 
The DNA fragment containing the codon 55 polymorphism was amplified using 
forward 5´- CCT GCA ATA ATA TGA AAC AAC CTG -3´ and reverse 5- ´TGA 
AAG ACT TAA ACT GCC AGT C -3´ (Sardo et al. 2005).  Reaction mixture was 
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prepared according to conditions stated above. After denaturation of DNA for 5 min 
at 94°C, the reaction mixture was subjected to 40 cycles of denaturation for 1 min at 
94°C, 45 seconds annealing at 55°C and 45 seconds extension at 72°C. Digestion was 
carried out with the Hsp92 II restriction enzyme (Promega Corporation, USA) and the 
fragments determined on a 3.5% agarose gel.  After digestion, the L allele was 
identified by a non-digested 172-bp fragment while the M allele was identified by 66-
bp and 106-bp fragments. 
 
In order to ensure accuracy of the genotypes assessed, each run had an internal control 
which was the same throughout all the runs.  Any ambiguous genotype was repeated 
and outliers were repeated twice to ensure accuracy of the genotype readout. 
 
Statistical methods 
The main objectives of this analysis were to evaluate a) the relationships between 
exposure status and cholinesterase levels; and b) relations between cholinesterase 
levels and PON1 activity, controlling for potential confounding factors such as 
smoking and drinking status; and whether these relations were modified by age, sex or 
ethnicity.  We also looked at factors affecting PON1 activity and measured the gene 
frequencies of the polymorphic alleles examined. 
  
The distributions of the variables were checked individually with histograms and 
standardised normal probability (P-P) plots.  In order to achieve normal distribution, 
cubic transformation was done on RBC AChE.  The significance of the differences in 
the mean values of levels of serum PChE and RCB AChE activities between exposure 
groups were tested using either Student’s t-test or one-way analysis of variance 
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(ANOVA) after ascertaining the homogeneity of variances.  Categorical variables (i.e. 
ethnicity, smoking status, alcohol consumption and PON1 genotypes) were studied by 
the chi-square test.  Deviation from Hardy-Weinberg equilibrium (HWE) was 
evaluated using chi-square tests. 
 
We then used multiple linear regression to assess predictors of serum PChE levels, 
controlling for covariates.  Models were constructed including known covariates (e.g. 
BMI, age and ethnicity) and other potential confounding variables such as smoking 
status, alcohol consumption and exposure duration.  Variables were retained in the 
final models if they were significantly associated with serum PChE levels (p≤0.05).  
Final models were assessed for the assumptions of linear regression and model fit 
using influence diagnostic procedures, examination of residuals and residual-predictor 
plots.  All statistical analyses were performed using Stata version 8.0 (Stata 
Corporation, USA).   
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RESULTS 
Descriptive Characteristics of the Study Population 
There were 103 exposed and 91 unexposed workers who participated in the study.  
The mean age of the 194 men was 36.9 (20–70) years with the unexposed group 
having a slightly lower mean age compared to the pesticide workers (35.0 and 38.3 
years respectively, p=0.039).  Our population was made up of 38.1% Chinese, 44.3% 
Malays and 17.5% Indians in total.    The mean ± SD exposure duration among the 
pesticide workers was 10.4 ± 8.4 years.  There were significantly more smokers in the 
exposed group (p=0.011) but no significant differences in drinking status between the 
two groups. The participants had a median BMI of 23.7 kg/m2 (95% CI: 22.8–24.5 
kg/m2) which is in the moderate health risk range (23–27.4 kg/m2) as defined by the 
Health Promotion Board, Singapore (2007), and there was no significant difference in 
BMI between the exposed and unexposed groups.  Among the exposed workers, 99% 
wore sufficient PPE.  Table 1 shows a summary of the characteristics of our study 
population.  The distribution of both genotypes were in HWE in the unexposed 
workers but the distribution of PON1Q192R was not in HWE in the exposed workers 
(p=0.0001).  With the main aim of detecting PON1 activity and genotypes, the study 
has achieved a power of 90% at a Type I error of 5% and an anticipated effect size of 






Table 1.  General characteristics of the study population. 
Variable Unexposed (n = 91) 
Exposed 
(n = 103) p 
a 
Serum PChE (U/L)b  9433.6 ± 2022.6 11028.4 ± 2867.4 < 0.0001
RBC AChE (U/L)b 18079.6 ± 1575.9 18436.2 ± 2077.9 0.216 
Age (years)b  35.0 ± 10.7 38.3 ± 10.3 0.039 
BMI (kg/m2)b  23.5 ± 3.9 24.5 ± 4.2 0.109 
Ethnicity (%)   
Chinese 37 (40.7) 37 (35.9) 
Malay 22 (24.2) 64 (62.1) 
Indian 32 (35.1) 2 (2.0) 
0.006 
Smoking status (%) 
Never 36.8 17.5 
Ex-smoker 14.5 20.4 
Current smoker 48.7 62.1 
0.011 
Drinking status (%) 
Do not drink 50.0 60.2 
Drink  occasionally 
(< 1 per week) 42.1 33.0 
Drink regularly (at 
least once a day) 7.9 6.8 
0.237 
Personal Protective Equipmentc 
Yes NA 99.0% 
No NA 1.0% 
— 
Exposure Duration 
(years)b NA 10.4 ± 8.4  
aVariables were compared by the Student’s t test or ANOVA 
bMean ± S.D. 
cUse of sufficient PPE. Management worker excluded. 
NA - Not applicable 
 
The exposed group was involved mainly in activities such as spraying, dusting and 
fogging.  The work site was usually around the size of one football field and covered 
mainly places such as residences (e.g. landed property and condominium dwellings), 
restaurants and factories.  They targeted general pests such as ants, cockroaches, 
termites, fleas, ticks, mosquitoes, bees, wasps and rodents.  Treatments were rendered 
as both preventive and curative measures, although prevention was cited slightly more 
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often as a reason.  All workers were directly involved in pest treatment in that they 
applied the pesticides themselves.  Only one worker reported not wearing PPE during 
pesticide application activities.  The rest put on adequate PPE consisting of gloves, 
respirator, goggles, dust coat, safety boots, helmet and ear muffler.  The primary 
application method was spraying, fogging and dusting, but also included misting, 
gelling, baiting, applying preventive beddings, oiling and fumigating.  Most workers 
entered the treatment site after application (77 %) and of those who re-entered, most 
continued to don their PPE during inspection (88 %).  Table 2 below shows the types 
of pesticides used by the workers in our study. Only five (20%) of the pesticides used 
contain OP. 
 
Table 2.  Commonly used pesticides among exposed workers in Singapore. 
Name Active ingredient Active against Contains 
OP 










Agita Thiamethoxam Fly   
Arsenic powder Arsenic trioxide Herbs, General 
Pests, Rodents 
  
Bentacide Cypermethrin Mosquito, 
Cockroach 
  
Biovectrol Etofenprox  Mosquito   
Chlorpyrifos Chlorpyrifos Cockroach Yes 






Table 2 (Contd.).  Commonly used pesticides among exposed workers in 
Singapore. 












Fentex Fenthion Mosquito Yes 
Fentrol Difenacoum Rodents   
Fogging 
solution 
Pyrethrin Mosquito   
Gokilaht Cyphenothrin Cockroach   
Larvicide Bacillus thuringiensis 
israelensis 
Mosquito Sometimes 
Malanon Malathion Mosquito   














Roban bait Bromadiolone Rodents   
Rodenticide Brodifacoum Rodents   
Sunmerin Alpha cypermethrin Cockroach   
Termidor Fipronil termites   
Value5 Cypermethrin Cockroach   
Vigon Propoxur Cockroach Yes 
*Information on active ingredients and effective targets obtained from NEA (2007) and Kegley et al. 
(2008). 
 
The neurological symptoms we studied were stomach pain, nausea, dizziness, 
difficulty in walking, numbness in the hands and feet, prickly sensations in the hands 
and feet, earache, tiredness in the arms and legs, pain in the arms and legs, runny 
nose, headache, drowsiness, heavy sensation on chest and tiredness.  There was no 
significant difference in reporting of neurological symptoms between the two 
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exposure groups, with 9.9% of the exposed workers reporting “Yes” for any symptom 
mentioned above and 10.4% in the unexposed group. 
 
Cholinesterase Measurements 
Cholinesterase levels between exposure groups 
The mean ± SD RBC AChE level was 18436.2 ± 2078 U/L and 18079.6 ± 1576 U/L 
for the exposed and unexposed groups respectively.  Although the exposed group had 
a slightly higher mean RBC AChE level than the unexposed group, this difference 
was not significant (p=0.216).  The mean ± SD serum PChE was 11028.4 ± 2867.4 
U/L and 9433.6 ± 2022.6 U/L in the exposed and unexposed groups respectively, with 
the exposed group having a significantly higher mean level than the unexposed group 
(p<0.0001). 
 
Cholinesterase levels between ethnicities 
When we looked at cholinesterase levels by ethnicity, there were no significant 
differences in serum PChE levels among the three ethnicities (Table 3).  However, 
RBC AChE levels were significantly different between the different ethnicities 
(p=0.040) with the Indians having a slightly lower mean RCB AChE level than the 
Chinese and Malays whose values were similar (9589.5 U/L vs. 10058.5 U/L and 
10745.7 respectively).  Likewise, the Malays and Chinese also shared similar mean 
serum PChE values of 10745.7 U/L and 10058.5 U/L respectively while the Indians 





Cholinesterase levels between groups, stratified by ethnicity 
When stratified by ethnicity, the difference between the mean RBC AChE levels in 
the exposed and unexposed groups was significant among Chinese (p=0.007) and 
Indians (p=0.032) but not in the Malays (p=0.323).  The difference in mean serum 
PChE levels between the exposed and unexposed groups was significant in Chinese 
(p=0.004) and Malays (p=0.043) but not in Indians (p=0.734).  Table 3 shows the 
summary of results of the cholinesterase measurements. 
 
Table 3.  Serum PChE and RBC AChE levels for each exposure group by  
ethnicity. 
Serum PChE [Mean ± SD (U/L)] RBC AChE [Mean ± SD (U/L)] Ethnicity 
Overall Exposed Unexposed Overall^ Exposed Unexposed 
Chinese 10058.5 
± 3075.6  
11078.9 
± 3711.6*  
9038.1 ± 




± 2173.9*  
17984.7 ± 
1789.6     
Malay 10745.7 
± 2149.1  
11026.4 
± 2288.1*  
9930.1 ± 




± 1809.1   
18294.6 ± 
1400.2      
Indian 9589.5 ± 
2472.4    
10179.5 
± 2815.0   
9552.6 ± 




± 1658.9*  
18032.1 ± 
1455.2     
^Differences between ethnic groups were significant (p<0.05) 
*Differences between exposed and unexposed groups were significant (p<0.05) 
 
Predictors of cholinesterase levels 
We next looked at the possible predictors of serum PChE and RBC AChE. The 
Pearson’s r for correlation between RBC AChE and serum PChE was only 0.151 with 
borderline significance (p=0.048).  Serum PChE independently had a positive 
correlation with BMI (r=0.362, p<0.0001), age (r=0.168, p=0.024) and POX activity 
(r=0.324, p<0.0001); but was not associated with ethnicity (χ2 p=0.065), smoking 
status (χ2 p=0.586) or drinking status (χ2 p=0.218) (Table 4).  Multiple linear 
regression models were constructed to assess these covariates as predictors of serum 
PChE levels.  Controlling for BMI, the results indicate that an increase of 1.0 U/L in 
POX activity was associated with an increase of 6.17 U/L in serum PChE levels.  
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BMI remained a significant factor in the relationship between serum PChE and POX 
activity even when the results were analysed separately according to exposure group.  
Interestingly, the positive relationship between serum PChE and POX activity was 
statistically significant with r=0.268 (p=0.007) in the exposed group whereas this was 
not seen in the unexposed group.  RBC AChE was independently associated with only 
race (p=0.024) and drinking status (p=0.023).  Multivariate analysis only left race as a 
significant predictor of RBC AChE (p=0.021). 
 
Table 4.  Correlation results of independent variables and serum PChE. 
Total Exposed Unexposed Variables 
r p-value   
BMI 0.362 <0.0001 r=0.285* r=0.468* 
Age 0.168 0.024 r=0.073 r=0.248* 
POX activity (U/L) 0.324 <0.0001 r=0.268* r=0.105 
*Correlation significant at p<0.05 
 
PON1 (Paraoxonase/Diazoxonase) Activity 
PON1 activity between exposure groups 
PON1 activity was determined by measuring PON1 enzymatic activity towards 
paraoxon and diazoxon (POX and DZO activities respectively).  The mean ± SD POX 
levels in the exposed and unexposed groups were 299.4 ± 135.0 U/L and 178.2 ± 58.1 
U/L respectively (p<0.0001).  The mean ± SD DZO levels in the exposed and 
unexposed groups were 1525.6 ± 635.0 U/L and 1929.3 ± 905.7 U/L respectively 
(p=0.0007). 
 
PON1 activity between ethnicities 
As described earlier, it has been established that PON1 activity differs across different 
ethnic groups; hence we investigated whether this was the case in our multi-ethnic 
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sample.  The mean ± SD levels of POX activity among the ethnic groups were 266.5 
± 119.4, 266.3 ± 131.2 and 165.6 ± 79.1 U/L for Chinese, Malays and Indians 
respectively (p=0.0003).  The difference between the Chinese and Malays was not 
statistically significant but the difference between Chinese and Indians, and Malays 
and Indians were both statistically significant with p=0.001.  When considering DZO 
activity, the mean ± SD levels of DZO activity among the ethnicity groups were 
1498.4 ± 695.8, 1673.7 ± 703.3 and 2127.4 ± 968.6 U/L for Chinese, Malays and 
Indians respectively (p=0.002).  A similar trend as that for POX activity was seen for 
DZO activity; in that the difference between the Chinese and Malays were not 
statistically significant but the difference between Chinese and Indians, and Malays 
and Indians were both statistically significant (p=0.001 and p=0.024 respectively). 
 
PON1 activity between exposure groups, stratified by ethnicity 
When we stratified the groups by ethnicity, it was found that the exposed in each 
ethnicity group had higher POX levels that the unexposed, and this difference was 
significant among the Chinese and Malays (p<0.001).  There were no significant 
differences between exposure groups stratified by ethnicity found for DZO activity.    
A summary of results for PON1 activity stratified by ethnicity is given in Table 5. 
 
Table 5. POX and DZO levels for each exposure group by ethnicity. 
POX [Mean ± SD (U/L)] DZO [Mean ± SD (U/L)] Ethnicity 
Overall^ Exposed Unexposed Overall^ Exposed Unexposed 




































^Differences in activity between ethnic groups were statistically significant (p<0.05) 
*Differences in activity between exposed and unexposed groups were statistically significant (p<0.05) 
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PON1 Genotypic Distribution 
PON1 genotypic distribution by exposure groups 
The next part of our project involved studying the genotypic distribution of the 
common PON1 polymorphisms, i.e. PON1Q192R and PON1L55M, in our local 
population.  Figure 8 shows the gel electrophoresis images of the PCR products after 
digestion by the respective restriction enzymes.  The results of our genotyping are 
shown in Table 6. 
                                       
                   
Figure 8. Genotyping of PON1Q192R (top) and PON1L55M (bottom) 
polymorphisms. Lanes a and b show homozygotes (RR) for the R allele while lanes c and d show 
heterozygotes (QR) for the PON1Q192R polymorphism.  Lanes f and h show heterozygotes (LM) for 
the PON1L55M polymorphism while lanes g and i show homozygotes for the L and M allele 
respectively (LL and MM respectively).  DNA ladder used in lane e was Bioline Hyperladder V. 
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For the PON1Q192R polymorphism, overall, the QR genotype was the most common, 
followed by RR then QQ.  When divided by exposure group, the exposed group had 
QR as the most common genotype, followed by RR then QQ; whereas in the 
unexposed group, QR was still the most common but QQ was more frequent than RR.  
For the PON1L55M polymorphism, the LL genotype was the most common, followed 
by LM then MM.  This trend remained the same even after stratification by exposure 
groups. 
 
PON1 genotypic distribution by ethnicities 
We next classified the data by ethnicity since ethnicity has an effect on the 
distribution of PON1 polymorphisms.   From the data, we see that overall, among 
Chinese, the QR genotype was the most common followed by RR then QQ (Table 6).  
This pattern was similar for the Malays whereas in Indians, QR was the most 
common, followed by QQ then RR.  For the PON1L55M polymorphism, the LL 
genotype was most common amongst Chinese, followed by LM and none had the 
MM genotype.  For the Malays, the trend was similar except that a small percentage 
(1.3%) had the MM genotype.  The trend amongst the Indians was somewhat similar, 
but here, the LL frequency was lower than the Chinese and Malays, with the LM and 
MM frequencies higher.  The differences between either of the polymorphisms and 







Table 6.  Distribution of PON1Q192R and PON1L55M genotypes. 
Overall By exposure group 
(%) 
By ethnicity (%)^ Genotype 






PON1Q192R       
QQ 15.5 11.4 20.6 3.6 13.0 42.9 
QR 59.0 48.9* 71.2 64.3 58.4 53.6 
RR 25.5 39.8* 8.2 32.1 28.6 3.6 
PON1L55M       
LL 80.8 87.5* 72.6 92.9 80.5 57.1 
LM 18.0 11.4* 26.0 7.1 18.2 39.3 
MM 1.2 1.1 1.4 0 1.3 3.6 
*Differences in genotype frequencies between exposed and unexposed groups were statistically 
significant 
^Differences in genotype frequencies between ethnicities were statistically significant 
 
PON1 alleles 
When we looked at PON1Q192R allele frequencies, the R allele was more common in 
the Chinese and Malays at 64.3% and 57.1% respectively (Table 7).  The Q allele was 
more common in the Indians at 69.6%.  For the PON1L55M polymorphism, the L 
allele was more common across all three ethnicities, with a higher percentage among 
Chinese and Malays (96.4% and 89.6% respectively) compared to Indians (76.8 %).  
We compared the genotyping data obtained from our study population with that 
obtained through genotyping on the Illumina 1M platform, which was part of a 
separate project (the Singapore Genome Variation Project), to check how similar the 
overall PON1Q192R allelic frequencies between the two groups were.  This 
genotyping had been done on a total of 96 Chinese, 89 Malays and 83 Indians in 
Singapore who were controls.  We could not compare PON1L55M allelic distribution 
as this was not available on the Illumina chip.  The allele frequencies were similar 
between our population and the population genotyped with the Illumina chip across 
the three ethnicities.  The R allele was still highest in the Chinese, followed by the 
Malays then Indians (Table 7). 
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Table 7.  Allelic frequencies of both PON1 polymorphisms by ethnicity. 
Distribution of alleles 
Genome Project Current study 
Genotype 
Chinese Malays Indians Chinese Malays Indians
PON1Q192R       
Q 0.276 0.393 0.542 0.357 0.429 0.696 
R 0.724 0.607 0.458 0.643 0.571 0.304 
PON1L55M       
L - - - 0.964 0.896 0.768 
M - - - 0.036 0.104 0.232 
 
PON1 genotypic distribution by exposure groups, stratified by ethnicity 
When we looked at the ethnic genotypic distributions of PON1 polymorphisms 
between the exposed and unexposed groups, the general trend of QR being the most 
common genotype among Chinese and Malays remained (Table 8).  There were only 
two exposed Indian workers, whose genotypes were QQ and RR respectively.  The 
QR genotype remained the most common genotype among the unexposed Indians, 
similar to the whole group trend seen above. 
 
Table 8.  Ethnic distribution of genotypes by exposure group. 








E U E U E U 
PON1Q192R    
QQ 3.5 3.7 14.0 15.0 50.0 42.3 
QR 48.3 81.5 50.9 75.0 0 57.7 
RR 48.3 14.8 35.1 10.0 50.0 0 
PON1L55M    
LL 96.6   88.9   84.2    70.0 50.0 57.7   
LM 3.5 11.1 14.0    30.0 50.0 38.5   
MM 0 0 1.8     0 0 3.9    






PON1 genotype and PON1 activity 
Next, we studied the effect of PON1 genotypes on PON1 activity since PON1 activity 
has been shown to vary according to different polymorphisms.  Table 9 shows the 
distribution of PON1 activity according to genotype in the population as a whole.  
POX activity increased according to the QQ<QR<RR genotypes for PON1Q192R 
whereas DZO activity increased in the reverse order.  This opposite trend between 
POX and DZO activity among the different genotypes was seen for PON1L55M as 
well, where POX activity showed decrease according to the LL>LM>MM genotypes 
of PON1L55M, whereas DZO activity increased in that order.  There was a 
statistically significant difference in the POX/DZO activities respectively when 
compared by genotype of the polymorphisms at both regions (PON1Q192R and 
PON1L55M) (p<0.0001).  When we looked at POX activity among participants with 
the same genotype between exposure groups, it was found that those in the exposed 
group had significantly higher levels of POX activity than the unexposed group for 
the QR and RR genotypes (e.g. mean POX activity in exposed RR was higher at 442.2 











Table 9.  PON1 activity by PON1Q192R and PON1L55M genotypes. 
POX activity  
[Mean ± SD (U/L)] 
DZO activity  
[Mean ± SD (U/L)] 
Genotype 
Overall# E U Overall# E U 
PON1 
Q192R 
      
























RR 412.6 ± 
107.4 












      
LL 268.3 ± 
130.7 * 
320.8 ±  
139.0 




















MM 107.3^  - 107.3^ 3309.1^ - 3309.1^   
#Differences in POX/DZO activity by PON1 genotype was tested with ANOVA.  p<0.001 for all 
instances. 
*Differences in POX/DZO activity between exposed and unexposed groups were significant. 
^1 observation 
E: Exposed, U: Unexposed 
 
PON1 Status 
As discussed previously, it has been argued that PON1 status provides more 
information than genotyping alone. Figure 9 shows the PON1 status of our entire 
study population obtained by plotting DZO activity on the y-axis vs. POX on the x-
axis.  As can be seen, individuals were sorted into three clusters of phenotypes of 
PON1Q192R activity – QQ, QR or RR.  This was verified by correlating the PON1 
status with results from genotyping the individual’s DNA (represented by the 
different symbols).  Similar clusters were seen when we looked at PON1 status by 
























Figure 9.  Plot of DZO vs. POX activity of the whole study sample.  Plotting of DZO 
vs. POX activity broke the population into three clusters, individual homozygous at position 192 for Q 
(closed circles) or R (open triangles) and heterozygotes (crosses) which have been confirmed by PCR.  
This analysis provides the PON1 phenotype (PON1 level) for each individual in the population. 
 
PON1 Genotypes and Cholinesterase Levels 
When we looked at serum PChE levels according to the PON1Q192R genotypes, we 
found an increasing trend among individuals with the QQ genotype (9757.5 ± 2334.3 
U/L), followed by QR (10215.7 ± 2303.3 U/L) then RR (11360.7 ± 3327.1 U/L) and 
the differences between the three groups were significant (p=0.028) (Table 10).  There 
was a decreasing trend observed for serum PChE levels stratified by PON1L55M 
genotypes in the order LL (10477.3 ± 2741.6 U/L), LM (10354.3 ± 2209.9 U/L) and 
MM (7523 U/L, one observation) but this did not reach a 5% level of significance 
(p=0.533).  Such trends were not seen for the associations between RBC AChE and 
either of the PON1 polymorphisms. 
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Table 10.  Serum PChE and RBC AChE levels by PON1 genotypes. 
Serum PChE 
levels (U/L) 




PON1Q192R *  
QQ 9757.5 ± 2334.3 18361.1 ± 2177.8 
QR 10215.7 ± 2303.3 18269.8 ± 1812.8 
RR 11360.7 ± 3327.1 18340.9 ± 2017.3 
PON1L55M   
LL 10477.3 ± 2741.6 18298.7 ± 1989.1 
LM 10354.3 ± 2209.9 18444.9 ± 1584.7 
MM 7523^ 16878.5 ± 1581.8 
*Differences in serum PChE levels between PON1Q192R genotypes were significant (p=0.028). 
^1 observation 
 
Factors affecting PON1 activity 
When we performed multivariate analysis to assess the predictors of POX activity, we 
found that serum PChE, exposure duration, smoking status, drinking status, DZO 
activity, PON1Q192R and PON1L55M genotypes were able to explain 74.5% 
(adjusted R2) of the variation in POX activity when we assessed the population as a 
whole.  However, when we performed regression by exposure group, only 
PON1Q192R genotype remained a significant predictor for POX activity in the 
unexposed (R2=50.9%), and PON1Q192R genotype and DZO activity remained 
significant in the exposed (R2=75.6%).  For DZO activity, only POX activity and 
PON1Q192R genotypes remained significant predictors of DZO activity (R2=43.6%).  
In the unexposed, only PON1Q192R remained a significant predictor of DZO activity 
(R2=40.5%) whereas in the exposed, both POX activity and PON1Q192R remained 




In the present study, workers involved in pesticide spraying activities were recruited 
to examine the relationship between pesticide exposure and possible health effects in 
the local population.  These workers are perpetually exposed to pesticides via two 
main routes – skin absorption during handling of concentrated formulation and 
inhalation during spraying activities and upon re-entering pesticide treated areas.  The 
study population consisted of 103 workers who were exposed to various kinds of 
pesticides in the line of work while the control group was made up of 91 workers 
from a lead stabiliser factory who were exposed to neither OP-containing nor any 
other kind of pesticides.  The men from the two groups were comparable in terms of 
age and health.  Since both their job scopes involved manual labour, we could also 
derive that their educational level and social economic status would not have varied 
much, hence making their comparability better.  Although the exposed group had 
significantly more smokers than the unexposed group, this factor did not become 
significant when we were doing multivariate analysis; hence the difference in 
smoking status was unlikely to have affected our results. 
 
Singapore is made up of a multi-ethnic society hence it was important that we 
collected data from the three major ethnic groups i.e. Chinese, Malays and Indians.  
These ethnicities make up a large percentage of the world population especially China 
and India thus it would be useful for these countries to take our results into 
consideration.  Although stratifying our analysis divided participants into groups with 
smaller numbers, it was important to do so since ethnicity plays a role in the genetic 
susceptibility to OPs.  One drawback of our study is that although the Chinese make 
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up the majority of Singaporeans (about 70%), followed by Malays and Indians, the 
population we sampled contained a higher percentage of Malays and Indians thus our 
sample was not representative of the general population.  Nonetheless, this would 
only affect generalisability of our results but we can still infer important observations 
for each ethnic group per se.  Another limitation is that instead of a control group that 
is from the general population i.e. not a group which is homogenous in terms of job 
exposure, we used workers from a lead stabiliser factory.  Thus, when comparing 
factors such as cholinesterase levels, the nature of their jobs might have slightly 
skewed the results.  For example, lead exposure might have been a confounder if it 
affects cholinesterase levels and PON1 activity among the unexposed.  Although we 
did not measure blood lead in our exposed workers there are no known reported 
studies among humans reporting an association between lead and RBC AChE, and no 
such association between lead and RBC AChE was found in our analysis when we 
looked for a correlation between cholinesterase levels and blood lead level in the 
unexposed (results not shown); hence lead was unlikely to be a confounder. This 
factor though, would not have affected the genotyping results as there is no genetic 
factor that predisposes individuals to choose one job industry over another.  It would 
also have been better to repeat this study on a larger sample since ours has a small 
number of participants.  The power of the test measuring PON1 activity between 
PON1 genotypes groups was, however, high suggesting that the differences observed 
are statistically valid.  The PON1 genotype frequencies in our study were comparable 
to other studies on the Singapore population, including the population genotyped on 
the Illumina platform and that done by Sanghera et al (1998) and therefore, one may 





The cross-sectional nature of our study was appropriate for fulfilling the purpose of 
our investigation which was to find out whether workers who were exposed to OP-
containing pesticides were in danger of toxicity.  This method enabled us to study the 
difference in cholinesterase levels between exposed and unexposed workers and also 
to study whether genotypes varied between the two groups.   Studied and discovered 
associations should make sense biologically and alleles should affect gene products in 
a way that is physiologically meaningful.  In the present study, we chose PON1 as a 
candidate gene because of the differences in the biological role between the various 
PON1 isoforms and postulated association with OP detoxification in humans.  
 
Questionnaire 
We administered a structured and detailed questionnaire which included information 
such as occupational history, presence of personal and family current/past medical 
conditions (if any) and any medicines taken in the past week as these might affect 
neurological symptoms presented.  The pesticide workers were given an additional 
questionnaire which detailed pesticide usage information such as frequency of use, 
areas treated and type of pesticides used.  One way that we could have improved the 
questionnaire was to list out, as complete as possible, a list of pesticides used by pest 
control companies in Singapore and to ask specific questions like “Have you ever 
personally mixed or applied this pesticide?”, “How many years did you personally 
mix or apply this pesticide?” and “In an average year when you personally used this 
pesticide, how many days did you it?”.  This is because we found that some of the 
workers were unable to recall the pesticides they used, while others were unable to 
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provide correct names of the pesticides used or give a list of each and every pesticide 
they had used.  Thus, we feel that some pesticides might have been left out or the 
details regarding how long each particular pesticide used might not have been precise.  
This would have been useful since we were zooming in on OP-based pesticides in 
particular.  In addition, recent studies point to the possibility of diet affecting PON1 
activity hence future questionnaires could include information such as vegetable and 
fruit intake. 
 
One of the limitations in the nature of the study being such that we had to administer 
questionnaires is that that the likelihood of recall bias regarding exposure and 
symptoms cannot be ruled out.  The exposed workers could have exaggerated 
symptom reporting upon realising that we were looking for the association between 
OP exposure and health-related effects since they have been educated on the likely 
symptoms of OP poisoning.  On the other extreme, they may hide the symptoms for 
fear of being suspended from OP work.  Conversely, unexposed workers could have 
been more forthcoming with symptom reporting since they are not familiar with OP 
poisoning symptoms.  This could explain why there were slightly more unexposed 
workers reporting “Yes” for neurological symptoms such as headaches and tiredness 
compared to the exposed workers which we did not expect, although the reporting of 
neurological symptoms between the two groups were not significantly different.  
There could also have been a tendency for the exposed workers to report usage of 
PPE even though they may not be actually using it in the field. We were not able to 
verify if what the workers reported were true.  Even if they were wearing PPE, we 
could not ascertain based on an oral interview if they were wearing the PPE correctly.   
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Nevertheless, use of PPE would not introduce a large bias to our findings as it was not 




It was essential to use lead-free polypropylene tubes that used heparin instead of 
EDTA as an anticoagulant as EDTA has been shown to inhibit PON1 activity (Richter 
and Furlong 1999; Pla et al. 2007; Golmanesh et al. 2008). Samples were stored in      
-80 °C until analysis so as to prevent degradation of enzymes.  Samples were 
separated into aliquots so that we could take out just a small amount that we needed 




The methods used to measure both cholinesterase levels were standard protocols. We 
ensured that all measurements were made within the same day as sample collection so 
as to prevent degradation of the enzymes. 
 
We did not measure nor had access to data regarding pre-exposure cholinesterase 
levels of the pest control workers.  Cholinesterase activity has large inter-individual 
variability hence it is important to collect baseline samples from each individual prior 
to exposure so that we can determine whether there has been any decrease in enzyme 
activity.  This depression needs to be at least 15% from normal (pre-exposure) levels 
to indicate over-exposure (Namba et al. 1971) and is a better method than comparing 
cholinesterase values with those from a normal, unexposed population.  However, this 
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may have been impossible to do in our population whereby there is no distinction 
between low exposure period and high exposure period since pest control activities 
take place continuously throughout the year unlike the agricultural settings presented 
in other studies where crops/animals are treated with pesticides only at certain times 
of the year.  A possible way to improve this situation would be to take serial 
measurements of cholinesterase levels at different time points and assess the level of 
variation. However, for the purpose of our study which is cross-sectional in nature, 
this was not done. 
 
PON1 activity measurements 
There are several substrates than can be used to measure PON1 activity.  
Phenylacetate, chlorpyrifos, paraoxon and diazoxon are among the common 
substrates used to measure the arylesterase, chlorpyrifos-oxonase, paraoxonase and 
diazoxonase activities of PON1 respectively.  In our study, we chose paraoxon and 
diazoxon because it has been found that plotting DZO activity vs. POX activity gave 
population frequency distributions that clearly separated individuals into the three 
genotypes – QQ, QR and RR (Davies et al. 1996). 
 
PON1 polymorphism screening 
We used PCR-RFLP to determine the genotypes of all individuals in our sample.  
Although this method is not as precise as DNA sequencing, it is still reliable in giving 
accurate genotypes once reaction conditions have been optimised.  We also took 
precautions to ensure that genotypes obtained were accurate by having internal 
controls and repetition of reads that were not definitive.  Furthermore, it is a much 
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more economical technique than say melt curve analysis and since we were only 
looking at two polymorphisms, PCR-RFLP was sufficient. 
 
Cholinesterase Measurements 
Cholinesterase has been shown in several studies to be inhibited in the presence of OP 
exposure (Panemangalore et al. 1999; Hernandez et al. 2005; Cataño et al. 2008).  We 
did not detect a drop in RBC AChE levels in exposed workers compared to unexposed 
workers as found in other studies of occupationally exposed workers (Tinoco-
Ojanguren and Halperin 1998).  This observation is understandable as most of the 
exposed workers are not exposed to OPs all the time in the course of their work. In 
fact, OPs only consisted of about 20% of the pesticides that they used (Table 2).  
Moreover, the exposed workers are required to undergo a medical surveillance every 
six months in which RBC AChE is measured.  If their RBC AChE levels are low, they 
would have been suspended from exposure to OP work. So far, none of the exposed 
workers have been suspended from OP work.  This low exposure to OP could also 
explain why we did not see any differences in symptoms reported between workers 
with different genotypes (data not shown) as was reported in previous studies 
(Mackness et al. 2003).  Another explanation for the absence of lowered RBC AChE 
level in the exposed group could be that exposure to minute amounts of pesticide 
could have led to upregulation of PON1 activity, as seen by the significantly higher 
PON1 activity in exposed workers with QR and RR genotypes compared to 
unexposed workers with these genotypes (Table 9).  
 
Serum PChE was also not lower in the exposed workers but in fact significantly 
higher than that of the unexposed workers. This observation could be an adaptation 
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mechanism for the exposed workers whereby exposure to OP compounds over time 
could have led to a higher enzyme activity (induction of serum PChE) that would 
reduce the binding of OP to biological targets , as previously suggested by Kashyap et 
al. (1984).  The positive relationship between serum PChE and POX activity which 
was statistically significant in the exposed workers could also mean that upregulation 
of POX activity could have prevented the inhibition serum PChE.  One also cannot 
rule out the possibility of the “healthy worker effect”.  This phenomenon occurs when 
workers who have sustainable PON1 activities are not affected by pesticide exposure 
hence they are able to continue in this line of work.  Indeed, this could be explained 
by the finding that there were many more exposed workers with the RR genotype 
(Table 6) which led to distortion of the HWE in this group.  However, we believe that 
upregulation of PON1 activity could also be a possible mechanism explaining the 
higher cholinesterase levels in exposed workers.  This is because when we examined 
POX levels among participants with the same genotype across exposure groups, it 
was found that those in the exposure group had higher levels of POX activity than the 
unexposed group (e.g. exposed RR mean POX activity was 442.2 ± 85.7 U/L, 
unexposed RR mean POX activity was 244.5 ± 40.7 U/L, difference statistically 
significant).  Another reason could be that almost all the exposed workers wore 
sufficient PPE during spraying activities.  This reinforces the idea that wearing proper 
PPE is essential in protection against health effects of OP exposure.  It would 
however, be important to encourage all pest control workers to continue using PPE 
during post-spraying site inspection as inhalation of pesticide aerosols still poses a 
risk.  This is in view of the fact that of those who re-entered pesticide treated areas, 
only 83.5% continued to put on their PPE.   
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The ethnic distribution of cholinesterase levels did not differ by much.  In both cases 
(RBC AChE and serum PChE), Chinese and Malays shared similar values while 
Indians had slightly lower values which was significant only for RBC AChE (Table 
3).  There were no clear trends in cholinesterase levels when we looked at values 
between the two exposure groups, stratified by ethnicity.  RBC AChE level was 
significantly higher in both the Chinese and Indian exposed vs. unexposed, but lower 
in Malay exposed vs. unexposed (not significant).  Serum PChE was significantly 
higher in the Chinese and Malay exposed vs. unexposed workers, but a similar 
difference between exposed Indians and unexposed Indians did not reach significance.  
Generally though, it seemed that the exposed had higher cholinesterase values when 
stratified by ethnicity and exposure group, analogous to the overall values obtained 
for the two groups. 
 
It is not surprising that the correlation between RBC AChE and serum PChE was low 
since the former is a marker of chronic exposure whereas the latter is more suitable 
for measuring acute toxicity.  The poor correlation corroborates previous findings 
which state that the two cannot be used as interchangeable markers to measure OP 
toxicity (Costa et al. 2005).  Although serum PChE independently correlated 
significantly with BMI, age and POX activity, only BMI and POX activity remained 
significant in multivariate analysis.  The positive correlation of serum PChE and BMI 
could be related to liver size.  It has been postulated that since serum PChE is 
synthesised in the liver before it is delivered to the blood stream, and since fat 
deposition in liver tissue stimulates the hepatic synthesis of serum PChE, this could 
explain why sufficient serum PChE was available in the exposed workers who had 
higher BMI than the unexposed (Cucuianu et al. 2002).  RBC AChE was significantly 
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associated with race in multivariate analysis.  This is in agreement with univariate 
analysis where RBC AChE levels were significantly different between the three 
ethnicities, with Malays and Indians having lower mean values than the Chinese. 
 
PON1 Activity, Status and Genotype 
The exposed group had significantly higher levels of POX than the unexposed group 
(299.4 U/L vs. 178.2 U/L respectively).  There could be a few reasons for this – either 
because there were more individuals with the RR genotype in the exposed group, or 
that POX levels were upregulated in the exposed workers, or a combination of both.  
Upregulation could have been possible since POX level in exposed workers with RR 
genotype was significantly higher than that in unexposed workers with the RR 
genotype (Table 9).  DZO levels were significantly higher in the unexposed compared 
to the exposed (1929.3 U/L vs. 1525.6 U/L respectively). This is not surprising 
because PON1’s ability to detoxify diazoxon is inverse of that to paraoxon.  Thus, if 
POX activity was higher in the exposed group, it would follow that DZO activity 
would be lower in the exposed group. 
 
When we compared PON1 activity across ethnic groups, the mean POX activity 
among Chinese and Malays were similar (266.5 U/L and 266.3 U/L respectively) 
whereas that of the Indians were significantly lower (165.6 U/L).    This is similar to 
the trend seen in genotypic distribution of the PON1Q192R and PON1L55M 
polymorphisms; whereby the pattern of the genotypic frequency distributions among 
Chinese and Malays followed closely, whereas the profiles among the Indians were 
more disparate.  This trend was even seen for the cholinesterase levels whereby the 
Chinese and Malays had closer mean values compared to the Indians.  Not 
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surprisingly, DZO mean values also followed this pattern; suggesting that ethnicity 
plays a big part in PON1 activity and also that Chinese and Malays are more similar 
than Indians when looking at ethnic disparities.  Even after stratification by groups, 
the Chinese still had the highest POX activity, followed by Malays then Indians. This 
can be explained by the fact that there were more Chinese with the R allele (higher 
activity allele) compared to Malays and Indians.  The increasing trend in DZO activity 
according to Chinese, Malays and Indians was only seen in the unexposed group after 
stratification by exposure group. However, the low DZO activity among the Indians 
could be due to the fact that the there were only two exposed Indians.  When we 
compared PON1 levels in participants with the same genotypes in different ethnic 
groups, we did not see any significant difference e.g. QQ Indians did not have POX 
activity that differed significantly from QQ Chinese. 
 
For the genotyping, in the Chinese and Malays the QR genotype was more prevalent 
than RR, followed by QQ which was present in low numbers.  The higher efficiency 
of PON1R192 in the Chinese and Malays could mean that they would be more 
protected against paraoxon-related pesticide poisoning, as suggested by Humbert et al. 
(1993).  The Q/R allele frequency among the Chinese was 0.64 and 0.36 for R and Q 
respectively (Table 7), echoing values found in other studies on Chinese populations 
where the R allele is more common that the Q allele (Padungtod et al. 1999; Zhou et 
al. 2000; Zhang et al. 2006).  Among the Malays the R allele frequency was 0.38, 
which is slightly lower than that found among a population of Malays from Malaysia 
where it was 0.59 (Poh and Muniandy 2007).  For Indians, the QR and QQ genotypes 
were more common than RR.  This was slightly different from two studies where the 
QQ genotype had the highest frequency, followed by QR then RR (Sanghera et al. 
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1997; Pati and Pati 1998).  This deviation could be due to the low numbers of Indians 
in our sample, especially in the exposed group.  Nevertheless the Q allele frequency in 
our Indian sample is still more prevalent than the R allele as mentioned in these 
studies (0.70 vs. 0.30).  Our values are close to those found in a study conducted by 
Sanghera et al. (1997), where it was found that Indians in Singapore had an R allele 
frequency of 0.33.  The consistently lower frequencies of QR in the Chinese and 
Malays in the exposed group could explain why the exposed had significantly a lower 
QR frequency overall.  Similarly, the consistently lower frequencies in the Chinese 
and Malays explains why the exposed had significantly higher RR frequency overall.  
This reasoning can also be used to explain the distribution of the L55M genotypes 
when examined between ethnicity and exposure groups. 
 
For the PON1L55M polymorphism, the LL genotype was the most common in all 
three ethnicities.  The M allele is so rare in Chinese that none of the Chinese 
participants had the MM genotype in this sample whereas 1.3% and 3.6% of the 
Malays and Indians, respectively, did.  The M allele is rare in almost all Chinese 
populations studied so far (Sanghera et al. 1998; Wang et al. 2003; Zhang et al. 2006). 
 
In our PON1 status analysis (Figure 2), it seemed that the distinction between the low 
and intermediate POX metabolisers was not clear but the distinction between 
intermediate and high metabolisers was clearer.  There were a few participants who 
genotyped as RR but phenotyped as QR.  As measures were taken to ensure accuracy 
in phenotypic and genotypic characterisation, it is unlikely that these anomalies were 
due to experimental error.  We believe that this is one of the examples where a 
functional genomic analysis provides more information than genotyping alone since 
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all polymorphisms (other than the two studied) are taken into account in finding out 
an individual’s PON1 function.  The ambiguity in the phenotype of the few 
participants could be explained by polymorphisms in other regions of the PON1 gene. 
Another probable explanation could be that one of the RR allele is silent, producing a 
phenotype than would be less active in detoxifying paraoxon as a homozygote would 
and resulting in an activity that is more similar to that of a QR  phenotype.  These 
speculations can be answered if we were to do sequencing of the PON1 gene 
belonging to these individuals. 
 
Serum PChE, exposure duration, smoking status, drinking status, DZO activity, 
PON1Q192R and PON1L55M genotypes appeared to be significant predictors of 
POX activity.  These factors have all been previously found to affect POX activity 
(Adkins et al. 1993; Humbert et al. 1993; Primo-Parmo et al. 1996; James et al. 2000; 
Kujiraoka et al. 2000; Cherry et al. 2002; Lee et al. 2003; Rao et al. 2003).  Upon a 
closer look though, only PON1Q192R genotype remained a significant predictor for 
POX activity in the unexposed, while PON1Q192R genotype and DZO activity were 
significant factors in the exposed.  The effects of the other factors were probably not 
strong enough to be retained in the final model.  Our finding that PON1Q192R 
genotype and/or DZO activity affects POX activity is not surprising since it has been 
established that POX activity is highly governed by PON1 genotypes.  And since 
PON1 activity is substrate dependent, the type of OP used (i.e. diazinon in this case) 
would have an influence on PON1 activity.  This also explains why the factors 
affecting DZO activity were the same as those affecting POX activity.  The 
PON1Q192R polymorphism seemed to have an effect on serum PChE levels, with 
increasing mean values in the order QQ<QR<RR.  This could reflect the effect of the 
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increasing PON1 activity in that order which would thus prevent inhibition of serum 
PChE in individuals possessing the R allele, hence highlighting the importance of this 
allele in OP detoxification. 
 
Recommendations Arising from the Study 
Workplace chemicals causing occupational illness is an imperative health problem.  
Genetic testing has the capability to estimate the possible risk especially for those 
workers who are genetically predisposed to have adverse effects to certain chemicals.  
There is substantial evidence from animal studies demonstrating a role for PON1 
polymorphisms in modulation of toxicity to several OPs, but still inadequate human 
evidence – should we propose PON1 status testing for workers using OPs such as 
parathion or chlorpyrifos?  Our study was too small to detect any significant 
difference in health effects between exposed and unexposed workers.  Thus, it would 
be preliminary at this stage for us to suggest genetic testing for workers dealing with 
OPs.  A recent study by Battuello et al. (2004) dealt with this question by estimating 
the effect of such genetic testing in 1000 workers who had various relative risks to OP 
toxicity.  Even at this number, they concluded that it is still preliminary for 
widespread genetic screening of PON1 status in OP-exposed workers to be 
recommended because of the high proportion of false-positive or false-negative 
results.  This highlights the urgency for further epidemiologic data detailing exposure 
and early health effects (e.g. blood AChE) so that the predictive value of such tests 
can be improved.  Ideally, other metabolic pathways should be taken into 
consideration when characterising the association between PON1 status and OP 
toxicity.  As mentioned earlier, the other enzymes involved in OP metabolism are 
polymorphic and this inevitably results in complicated and diverse interactions 
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between numerous genes that will impact differences in dose-response and toxicity 
risk.  It would be additionally useful if these studies were conducted in Asian 
countries so that results can be extrapolated to our own population rather than relying 
on data from ethnically different populations such as Caucasians which could be very 
different from the true scenario among Asians. 
 
On another note, the information obtained from this study could be relevant for 
relevant anti- biochemical terrorism agencies on the possible risks involved in the 
event of an OP attack.  Our data suggests that Malays and Chinese in Singapore have 
high frequencies of the R and L alleles.  From this, we would assume that in the event 
of OP poisoning, the Malays and Chinese would be more protected against paraoxon-
containing pesticides since they have the allele with higher catalytic activity towards 
paraoxon (R), as well as the allele which confers higher plasma PON1 levels (L).  On 
the other hand, Indians seem to have more of the M and Q alleles, suggesting lower 
plasma PON1 levels and more protection against diazoxon, sarin and soman instead 
of paraoxon.  However, in view of the fact that the OP agents used in biochemical 
terrorism include sarin and soman, it appears that the burden on our medical rescue 
care could be potentially high in the event of an unfortunate attack since Malays and 
Chinese make up the majority of our population.  Therefore the relevant anti-
biochemical terrorism agencies should be alerted of this likely casualty rate in the 
event of an OP attack to allow them to work out appropriate medical support plans. 
 
Future Prospects 
Several studies have indicated the possibility of long term effects of OP exposure on 
health (Hernandez et al. 2005; Lopez et al. 2007; Cataño et al. 2008).  It would be 
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interesting to study whether our pesticide workers will develop more symptoms upon 
longer exposure to OP compounds.  Other investigations have pointed out to 
environmental variables that influence PON1 levels, including smoking (James et al. 
2000; Jarvik et al. 2002; Ferre et al. 2003; Senti et al. 2003), alcohol consumption 
(Van Der Gaag et al. 1999; Sierksma et al. 2002; Ferre et al. 2003; Rao et al. 2003; 
Sarandol et al. 2003; Vincent-Viry et al. 2003), vitamin intake (Kleemola et al. 2002; 
Rosenblat et al. 2003); (Ferre et al. 2003), fat-rich diets (Tomas et al. 2001; Wallace 
et al. 2001; Nguyen and Sok 2003) and physical activity (Tomas et al. 2002; 
Goldhammer et al. 2007).  The effect of some of these factors on PON1 activity has 
already been tested but there is a rising need to know more about these factors that 
alter the actions of PON1, especially in relation to PON1 genotype.  Studies on gene-
environment interactions afford new ideas in the field of genetic studies and although 
they are challenging, they are urgently needed (Wallace et al. 2000).  Numerous 
simultaneous gene-gene and gene-environment interactions such as PON1, vitamin 
intake and diet, will, however, complicate the interpretation of results. 
 
Epidemiological studies have proposed other mechanisms that may link pesticide 
exposure to health outcomes.  These mechanisms are mechanical and include DNA 
damage and oxidative stress (Singh et al. 2007; Muniz et al. 2008).  Pesticides are 
believed to have low genotoxic potential, but monitoring genotoxicity in exposed 
workers could be a beneficial way of estimating genetic risk from exposure to 
different pesticides over time (Moller et al. 2000).  Possible methods of studying 
genotoxic biomarkers would be by focusing on cytogenetic endpoints such as 




Exposure to different pesticides has been reported to be associated with both in vitro 
and in vivo changes in δ-aminolevulinic acid dehydratase (ALA-D), an erythrocyte 
enzyme (Panemangalore et al. 1999; Hernandez et al. 2005).  Furthermore, 
polymorphisms in cytochromes P450 (CYP), glutathione-S-transferases (GST) as well 
as of RBC AChE and serum PChE have also been suggested to have a role in 
pesticide susceptibility. Therefore, these enzymes and their polymorphisms could 
become sensitive biomarkers that can be used together with PON1, RBC AChE and 
serum PChE levels for assessing long-term health effects of pesticide workers. 
 
Comprehensive studies taking into account the various suggestions above should be 
undertaken to possibly solve the long debated question of whether PON1 status 
should be screened.  With relevance to pesticide exposed workers, this would be 
beneficial so that those who have genotypes which have higher predispositions to 
toxicity could be advised to take up other jobs.  This however would possibly open up 
the Pandora’s Box of confidentiality and ethics whereby people with a certain 










SUMMARY AND CONCLUSIONS 
This cross-sectional study was done in a group of pesticide workers in order to assess 
the level of toxicity caused by OP-containing pesticides.  Serum PChE and RBC 
AChE levels were used as surrogate markers of toxicity.  Our purpose was also to 
study the PON1 status and genotypes in the local population and whether this had an 
effect in OP susceptibility.  We also took the opportunity to find out if other suggested 
factors such as BMI, smoking, drinking and exposure duration had any effect on 
PON1 levels.  The main findings and conclusions of this thesis are: 
1. Neither serum PChE nor RBC AChE was inhibited in our exposed workers.  In 
fact, their levels were higher compared to the unexposed workers, suggesting that 
a possible adaptation mechanism such as induction of the cholinesterases could 
have taken place. 
2. There was high compliance of PPE usage among pesticide workers indicating that 
safety education and regulations have been useful in encouraging the use of PPE 
for the safety of our workers.  This also gives some assurance that the threat of OP 
poisoning among pesticide workers would be low since they are well protected.  
This has been backed by the low figures of exposed workers reporting 
neurological symptoms. 
3. Ethnicity seemed to have an influence on the parameters we studied.  The general 
trend was that Chinese and Malays had more similar patterns of enzyme level as 
well as genotypic distribution, whereas that of the Indians was more disparate.  
This emphasises the importance of stratifying such studies by ethnicity for greater 
accuracy of result interpretation. 
4. POX activity was higher in the exposed group than the unexposed groups, 
possibly due to the higher percentage of workers with the high activity allele (R), 
 76
upregulation of their POX levels, or a combination of both reasons.  POX activity 
differed by ethnicity, with Chinese and Malays having higher activity than 
Indians.  This can be explained by the fact that the R allele was found in higher 
numbers among the Chinese and Malays.  This would mean that in the event of 
poisoning by OPs such as parathion, Chinese and Malays would be more 
protected than Indians.  Conversely, in the unfortunate event of a terrorist attack 
using OP agents such as sarin, Chinese and Malays would be at greater risk since 
the R allele is less efficient at detoxifying this group of OPs.  This information is 
highly important for planners of anti-bioterrorism agencies because in Singapore, 
Chinese and Malays make up a large majority of the population.  Should such a 
tragedy happen, the local anti-bioterrorism agencies would need to be prepared for 
the potentially high casualty rates. 
 
In conclusion, this study suggests that the PON1Q192R genotype (more than the 
PON1L55M genotype) is an important genetic factor in determining susceptibility to 
OP compounds.  Ethnicity could be a surrogate marker for OP susceptibility since 
PON1 activity varied according to genotypic patterns found in particular ethnic 
groups.  The impact of PON1 on cholinesterase levels is evident as seen by the 
increased serum PChE levels in workers with higher POX activity.  Although the 
threat of OP poisoning among occupationally exposed workers is rare in Singapore, 
this information would useful for other developing countries that have large 
populations of Chinese, Malays and Indians where OP exposure could be very high 
especially in agricultural settings.  Investing in long term studies to follow up whether 
pesticide workers develop neurological symptoms would be worthwhile so that we 
can have a more comprehensive idea about the chronic effects of OP exposure.  This 
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together with studying gene-gene and gene-environment factors might help in 
developing new strategies for the prevention of OP toxicity and its complications in 
other more at-risk populations. 
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Date of Examination: __________________        Ref No: _________________ 
 
 




I Personal Particulars 
 
 
Name: _____________________________       NRIC: ___________________    
  
 
Date of birth: __________________     
 
 
Sex: Male  Female     
 
 
Race: Chinese  Malay  Indian  Others 
 
       
Address: _______________________________________________________ 
 













Date of Joining Factory: ________________________ 
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II Smoking History 
 Are you currently smoking cigarettes/pipe? 
  1.  Non-smoker 2.  Cigarettes  3.  Pipe 
 
For current cigarette smokers: 
1. How many sticks do you usually smoke per day? 
________________ sticks 




Have you ever smoked cigarettes/pipe in the past? 
1.  Never  2.  Cigarettes   3.  Pipe 
 
For ex-cigarettes smokers: 
1. How many sticks do you usually smoke per day? 
________________ sticks 
2. At what age did you start smoking? 
___________________________ 
3. At what age did you quit smoking? 
___________________________ 
 
III Do you drink alcohol? 
1. No 
2. Yes, occasional & social drinker 
3. Yes, regular drinker (at least once a week regularly) 
 
IV Medical History 
 
 Have you ever been told by your doctor to have: 
  a.  high blood pressure? 1.  Yes  2.  No 
  b.  diabetes mellitus?  1.  Yes  2.  No 
  c.  kidney diseases?  1.  Yes  2.  No 
d.  nervous disease?   1.  Yes  2.  No 




Have any of your family members (parents/siblings) been told by their doctors 
to have: 
a.  high blood pressure? 1.  Yes  2.  No  3.  Don’t know 
b.  diabetes mellitus?  1.  Yes  2.  No  3.  Don’t know 
 c.  kidney diseases?  1.  Yes  2.  No  3.  Don’t know 








V Drug History 
Are you currently on any long term medication? ________________________ 
 
For the last two weeks, were you on any of the following medication? 
a.  Panadol?   1.  Yes  2.  No 
b.  Aspirin/Salicylates? 1.  Yes  2.  No 
c.  Antibiotics?  1.  Yes  2.  No   
d.  Others? ______________________________________________________ 
 
VI Occupational History 
 



















VII Specialized Questionnaire  
 
Refer to separate questionnaire and only for exposed workers. 
    
 
VIII Medical Examination 
 
 Height: ___________________cm           Weight: ___________________kg 
Blood pressure: ______________________ 
Clinical examination: 
1. No abnormalities 


















Did you experience any of the following symptoms over the past two weeks: 
 
 Yes No 
STOMACH PAINS/ACHES   
If so, did it last for more than three months?   
   
FELT LIKE VOMITING   
If so, did it last for more than three months?   
   
LIGHT HEADED / DIZZY    
If so, did it last for more than three months?   
   
DIFFICULTY WALKING    
If so, did it last for more than three months?   
   
NUMBNESS IN HANDS OR FEET   
If so, did it last for more than three months?   
   
PRICKLY SENSATION IN HANDS OR FEET    
If so, did it last for more than three months?   
   
EARACHE     
If so, did it last for more than three months?   
   
TIREDNESS IN ARMS AND LEGS   
If so, did it last for more than three months?   
   
PAIN IN ARMS AND LEGS   
If so, did it last for more than three months?   
   
RUNNY NOSE    
If so, did it last for more than three months?   
   
HEADACHE   
If so, did it last for more than three months?   
   
DROWSINESS      
If so, did it last for more than three months?   
   
HEAVY SENSATION ON YOUR CHEST    
If so, did it last for more than three months?   
   
TIREDNESS                                        
If so, did it last for more than three months?   
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Specialised Questionnaire  
Exposed workers ONLY 
 
Nursery workers, Workers with National Park Board / Primary Production Department 
(former), Golf course workers who maintain the greens 
 




2. For crop growing, what crops were you involved in growing, handling or  
spraying? 
 
Outside Yes Acres Start year-
end year 
None |__|   
Fruit trees |__|   
Mushrooms |__|   
Vegetables |__|   
Flowers |__|   
Other (please specify) |__|   
    
In greenhouses 
Yes Size of the 





|__|   
Greenhouse flowers 
Specify : 
|__|   
Mushrooms |__|   
Other 
Specify : 
|__|   
 Yes Start year-end 
years 
Size of workplace 
(Hectares) 
Pest control |__|   
Flower growing |__|   
Golf Course  |__|   
Orchards |__|   
Gardening / 
park keeping 
|__|   
Packing of 
Pesticides 
|__|   
Vegetable 
gardening 
   
Other - specify: |__|   
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3.  Were you involved in applying pesticides?  Yes |__|  No |__|  DK |__|  
 
3.1 If yes: 
What items were 
treated? 
For what pests 
was this item 
treated? (1) 
















this pesticide?  
If yes, what? (4) 
What application method 
was used?  
 
NB, did the method change 
over time? (2) 
What pesticide was used? 
(3) 
 
NB, did the pesticide 







Period of use of 
this pesticide 
























        
(1) Insects, weeds, fungi. What kind of insects, weeds, fungi? 
(2) Backpack, handgun spraying, application from truck/lorry, fumigation, high-volume airblast application, ultra low-volume application, aerial 
mounted spray 
(3) Can you recall the names of the products? If not, can you say if it was a liquid or powder, what colour it had? 
(4) E.g. overalls/working clothes/handkerchief over mouth/filter mask/cabin on truck. 
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4.  Did you clean the equipment, or the tools used for the pesticide 
treatments?  
Yes |__|  No  |__|  DK |__|  
 4.1 If yes, how many days a year? __________________ 
4.2 If yes, did you use petrol or other solvents?  
Yes |__| No |__|  DK |__|  
 
 
5. Did you enter the field after it was treated? 
5.1  If yes, to do what?  
     ________________________________ 
5.2  How many days a year did you enter the field after it was treated? 
     _________________________________ 
5.3  Did you use any protective equipment while entering the field?  
     Yes |__|  No  |__|  DK |__| 
     If yes, what: __________________________ 
 
 
6.        Did you treat the soil with fumigants? Yes |__|  No  |__|  DK |__| 
           6.1 If yes, how often did you treat the soil with fumigants? 
           ____________________________________________________ 
           6.2 What fumigant was used? 
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